Paid Clinical Trials - 82,000 Members & Growing

  • Paid Clinical Trials
  • About Us
  • Auto-Updates
  • FAQ's
  • Quick Start Guide
www.GlobalTestMarket.com

 

Find Paid Clinical Trials Join Paid Clinical Trials ...

PaidClinicalTrials.org is a registry of compensated and uncompensated, federally and privately supported clinical trials conducted in the United States and around the world. Here you will find information about a trial's purpose, who may participate, locations, and phone numbers.

 

Find Paid Clinical Trials Clinical Trial Seekers - PCT is a public service, sponsor supported, clinical trial database that may be accessed by the general public at no charge in accordance with our terms of service use.

Clinical trials are added and removed each day on a 30 day rotation. For accuracy - We only list clinical trials that have been reported to these government agencies in the last 30 days:

 

U.S. National Library of Medicine,
U.S. Department of Health & Human Services
U.S. National Institutes of health Services.







Paid Clinical Trials - Auto Update Service

If you would like to receive timely and important notifications about new clinical trials in your area please fill out this short form. There is never any cost for our notification services. We value your privacy, your email address and member information is NEVER shared!

*  Your Email Address:
*  Preferred Format:
    Title:
    First Name:
    Country:
    State (US):
    City (UK):
    Territory (AU):

Tips for Finding Clinical Trials

 

One of the toughest and most-time consuming parts for medical research staff conducting the clinical trials is actually finding volunteers willing to participate. Research staff are looking for you! There are numerous ways to identify clinical trials looking for healthy human volunteers.

 

Trials are actively conducted by hospitals, universities, foundations, and contract research organizations (CROs, firms that conduct studies for big pharmaceutical and biotechnology companies). According to CISCRP, nearly 40% of these clinical trials can be learned about through media such as tv, radio, or printed ads. While finding studies through tv and radio ads might be difficult, you can actively scour the wanted section of your local newspapers to find trials.

Most local research clinics run ads for volunteers in the local newspaper, employment papers, on TV, and on the radio. They also post ads on Craigslist and on their own websites. Call them up as soon as you see something of interest. If the study is no longer recruiting volunteers, they might enter you in there database for future study participation.

 

Look up local research clinics in your phone book and ask (a) if they have any studies openly recruiting healthy volunteers and (b) if you could be entered into their volunteer database.

College campuses and major universities with research hospitals are also great places to find clinical trial. Schools of medicine, dentistry, and nursing, along with departments of psychology, sociology, and communications, at local universities, are always looking for willing volunteers for their experiments. Perform an internet search for the hospitals, schools, and departments on nearby campuses, then look for any section concerning clinical trials or research volunteers.


When searching for clinical trials on our website you will click on a Clinical Trial Information sheet like this example. Find Paid Clinical Trials Example Information Sheet. The first thing you should do is to see if the clinical trial is right for you. You can do this by quickly scanning the headings of the information sheet. These headings are highlighted on the left by blue icons as follows:


  >> Status of the Clinical Trial (This will appear at the top in red or green)


Purpose - This will briefly let you know about the clinical trial and how it is conducted.


Eligibility - This tells you age, gender and health status information. If you do not meet these eligibility requirement you should move to another clinical trial.


Contacts and Locations - This will list the locations the clinical trial is being conducted and it will usually list the contact person to call. Note - Even if your location is not listed you should call the clinical trial investigator. Sometimes their locations have not been updated or they are willing to pay time and travel expenses.


More Information - This will often give alternative contact people and other pertinent information about the trial.

These headings appear on the left side of the information sheet and are fairly self explanatory. Doing this will help you to quickly evaluate if the clinical trial is right for you.

 


 

Paid Clinical Trials Searching Tips

 

Paid Clinical Trials Check the Conditions Category - If you only search the "Locations" directory you are missing out on a lot of clinical trials. Trials that are listed by "Condition" usually have multiple locations and can add new locations as the study moves forward.

 

Paid Clinical Trials Register Your Profile with us. - You can post your location and condition in our personal clinical trials directory for FREE. This helps the research recruiters find you when the right trial becomes available. Register for Clinical Trials Here.

 

Paid Clinical Trials Call the Clinical Trial Recruiters - At the bottom of all the information sheets you will see a "Contact Information" heading. Many clinical trials can be conducted in remote locations and the recruiters can help you.

 

Paid Clinical Trials Subscribe to our Auto Update Service - By subscribing to our Auto Update Service you will receive automated emails informing you when new trials have opened in your area.

Sponsored Links







  • Conditions:   Myelodysplastic Syndrome (MDS);   Chronic Lymphocytic Leukemia (CLL);   Chemotherapy-sensitive Lymphoma;   Acute Lymphoblastic Leukemia (ALL)/T Lymphoblastic Lymphoma;   Acute Myelogenous Leukemia (AML);   Acute Biphenotypic Leukemia (ABL);   Acute Undifferentiated Leukemia (AUL)
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5;   Radiation: Total Body Irradiation (TBI) 200cGy on Day -1;   Procedure: Infusion of non-T-cell depleted bone marrow on Day 0;   Drug: Busulfan;   Drug: Cyclophosphamide 50mg/kg/day IV on Days -2,-1;   Drug: Cyclophosphamide 50mg/kg/day IV on Days -5,-4;   Radiation: Total Body Irradiation (TBI) 200cGy twice a day on Days -3, -2, -1;   Drug: Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4;   Drug: Sirolimus;   Drug: Mycophenolate mofetil;   Drug: G-CSF;   Drug: Pre-HCT Mesna on Days -6 and -5;   Drug: Pre-HCT Mesna on Days -2 and -1;   Drug: Pre-HCT Mesna on Days -5 and -4;   Drug: Post-HCT Mesna
    Sponsors:   Center for International Blood and Marrow Transplant Research;   National Marrow Donor Program;   Resource for Clinical Investigation in Blood and Marrow Transplantation
    Not yet recruiting - verified June 2016

  • Conditions:   Breast Cancer;   Metastatic HER2-negative Breast
    Interventions:   Drug: Cyclophosphamide;   Biological: Mesothelin-targeted T cells;   Drug: AP1903
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting - verified June 2016

  • Conditions:   Acute Lymphoblastic Leukemia (ALL);   Acute Myeloid Leukemia (AML);   Myeloid Sarcoma;   Chronic Myeloid Leukemia (CML);   Juvenile Myelomonocytic Leukemia (JMML);   Myelodysplastic Syndrome (MDS);   Non-Hodgkin Lymphoma (NHL)
    Interventions:   Drug: Anti-thymocyte globulin (rabbit);   Drug: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: G-CSF;   Drug: Melphalan;   Drug: Mesna;   Drug: Rituximab;   Drug: Tacrolimus;   Drug: Thiotepa;   Biological: HPC,A Infusion
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting - verified June 2016

  • Condition:   Leukemia, Myeloid, Acute
    Interventions:   Biological: PNK-007;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Human recombinant Interleukin-2 (rhIL-2)
    Sponsor:   Celgene Corporation
    Not yet recruiting - verified June 2016

  • Condition:   Breast Cancer
    Interventions:   Drug: paclitaxel;   Drug: Trastuzumab;   Drug: Pertuzumab;   Drug: Carboplatin;   Procedure: Breast surgery;   Drug: AC
    Sponsors:   William Sikov;   Women and Infants Hospital of Rhode Island
    Not yet recruiting - verified May 2016

  • Condition:   Neuroblastoma
    Interventions:   Drug: Topotecan;   Drug: Cyclophosphamide;   Drug: Cisplatin;   Drug: Etoposide;   Drug: Vincristine;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Sargramostim
    Sponsors:   Baylor College of Medicine;   Texas Children's Hospital
    Not yet recruiting - verified June 2016

  • Condition:   Acute Myeloid Leukemia
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Single dose total body irradiation;   Procedure: Graft cell infusion;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: G-CSF;   Procedure: CIML NK cell infusion;   Drug: ALT-803;   Procedure: Leukapheresis
    Sponsor:   Washington University School of Medicine
    Not yet recruiting - verified May 2016

  • Conditions:   Recurrent Epithelial Ovarian Cancer;   Recurrent Fallopian Tube Cancer;   Recurrent Peritoneal Cancer
    Interventions:   Biological: DPX-Survivac;   Drug: Cyclophosphamide;   Drug: Epacadostat (INCB024360)
    Sponsors:   ImmunoVaccine Technologies, Inc.;   Incyte Corporation
    Recruiting - verified June 2016

  • Conditions:   HLA-A2 Positive Cells Present;   Metastatic Malignant Neoplasm;   Metastatic Malignant Neoplasm in the Brain
    Interventions:   Biological: Aldesleukin;   Biological: Anti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes;   Drug: Cyclophosphamide;   Biological: Filgrastim;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis
    Sponsors:   Albert Einstein College of Medicine of Yeshiva University;   National Cancer Institute (NCI)
    Not yet recruiting - verified May 2016

  • Conditions:   Adult Solid Neoplasm;   Childhood Solid Neoplasm;   Metastatic Neoplasm
    Interventions:   Biological: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Biological: NY-ESO-1 Reactive TCR Retroviral Vector Transduced Autologous PBL;   Biological: NY-ESO-1(157-165) Peptide-pulsed Autologous Dendritic Cell Vaccine;   Procedure: Positron Emission Tomography
    Sponsors:   Jonsson Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Not yet recruiting - verified March 2016

  • Conditions:   Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myelogenous Leukemia;   Myelodysplasia
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: TBI;   Drug: CsA;   Drug: MMF;   Biological: Unmanipulated UCB;   Biological: SR-1 UCB;   Biological: G-CSF
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Not yet recruiting - verified May 2016

  • Condition:   Sickle Cell Disease
    Interventions:   Procedure: Bone Marrow Transplant (BMT);   Procedure: Bone Marrow Harvest (Donation);   Drug: Hydroxyurea;   Drug: Thiotepa;   Drug: Fludarabine monophosphate;   Drug: Cyclophosphamide;   Other: Rabbit Anti-thymocyte Globulin;   Radiation: Total Body Irradiation
    Sponsor:   Emory University
    Recruiting - verified April 2016

  • Condition:   Gastrointestinal Cancer Metastatic
    Interventions:   Drug: Standard Chemotherapy;   Drug: Cyclophosphamide;   Biological: Adoptive T Cell Infusion;   Drug: IL-2;   Drug: Pembrolizumab;   Behavioral: Phone Calls
    Sponsors:   M.D. Anderson Cancer Center;   Merck Sharp & Dohme Corp.
    Not yet recruiting - verified April 2016

  • Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndrome;   Acute Lymphocytic Leukemia
    Interventions:   Drug: Fludarabine;   Radiation: Fractionated total body irradiation;   Drug: Busulfan;   Drug: Cyclophosphamide;   Radiation: Single dose total body irradiation;   Drug: Melphalan;   Drug: Granulocyte-colony stimulating factor;   Procedure: Stem cell transplant;   Drug: Azacitidine
    Sponsor:   Washington University School of Medicine
    Not yet recruiting - verified May 2016

  • Conditions:   Leukemia;   Lymphoma;   Myeloma;   Myeloproliferative Diseases
    Interventions:   Drug: Busulfan;   Drug: Fludarabine;   Drug: Clofarabine;   Drug: Rabbit ATG;   Radiation: Total Body Irradiation (TBI);   Procedure: Cord Blood Infusions;   Drug: Rituximab;   Drug: Cyclophosphamide;   Procedure: Natural Killer Cell Infusion;   Drug: Melphalan;   Drug: Mesna
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting - verified May 2016

  • Condition:   Untreated Childhood Medulloblastoma
    Interventions:   Drug: Cisplatin;   Drug: Cyclophosphamide;   Other: Laboratory Biomarker Analysis;   Drug: Lomustine;   Radiation: Radiation Therapy;   Drug: Vincristine Sulfate
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Not yet recruiting - verified March 2016

  • Conditions:   Acute Leukemia;   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia/Lymphoma;   Burkitt's Lymphoma;   Natural Killer Cell Malignancies;   Chronic Myelogenous Leukemia;   Myelodysplastic Syndrome;   Large-cell Lymphoma;   Hodgkin Lymphoma;   Multiple Myeloma;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Marginal Zone B-cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-cell Lymphoma;   Prolymphocytic Leukemia;   Bone Marrow Failure Syndromes;   Myeloproliferative Syndromes
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: MMF;   Drug: Sirolimus;   Radiation: TBI;   Biological: Umbilical cord blood cell infusion;   Biological: ATG
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Not yet recruiting - verified April 2016

  • Condition:   Early Stage Breast Cancer
    Interventions:   Drug: Paclitaxel;   Drug: Neulasta;   Drug: Cyclophosphamide;   Drug: Doxorubicin
    Sponsor:   Dana-Farber Cancer Institute
    Recruiting - verified May 2016

  • Conditions:   Fibrolamellar Hepatocellular Carcinoma;   Hepatocellular Carcinoma (Fibrolamellar Variant);   Hepatocellular Carcinoma
    Interventions:   Procedure: living related donor partial liver transplantation;   Radiation: Total body irradiation;   Procedure: Bone marrow transplant from same donor;   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Filgrastim;   Drug: Tacrolimus;   Drug: mycophenolate mofetil;   Drug: Prednisone;   Drug: Antithymocyte globulin;   Drug: fludarabine
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Fibrolamellar Cancer Foundation
    Recruiting - verified May 2016

  • Conditions:   Diffuse Large B-Cell Lymphoma, Not Otherwise Specified;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Mediastinal (Thymic) Large B-Cell Cell Lymphoma
    Interventions:   Biological: JCAR014;   Drug: Cyclophosphamide;   Biological: Durvalumab;   Drug: Fludarabine Phosphate;   Other: Pharmacological Study
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   Juno Therapeutics;   MedImmune LLC;   AstraZeneca
    Not yet recruiting - verified March 2016

  • Conditions:   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Ependymoma;   Childhood Atypical Teratoid/Rhabdoid Tumor;   Embryonal Tumor With Abundant Neuropil and True Rosettes;   Metastatic Malignant Neoplasm to the Leptomeninges
    Intervention:   Drug: Intra thecal methotrexate
    Sponsor:   Nicklaus Children's Hospital f/k/a Miami Children's Hospital
    Recruiting - verified February 2016

  • Condition:   Sickle Cell Disease
    Interventions:   Drug: Alemtuzumab;   Drug: Cyclophosphamide;   Drug: Mycophenolate mofetil;   Drug: Sirolimus;   Drug: Fludarabine;   Radiation: Total body irradiation;   Procedure: Hematopoietic stem cell transplant
    Sponsor:   Washington University School of Medicine
    Recruiting - verified May 2016

  • Conditions:   Lymphoma, B-Cell;   Lymphoma, Non-hodgkins;   Lymphoma, Hodgkins;   Leukemia, B-cell
    Interventions:   Biological: Anti-CD19-CAR T cells;   Drug: Cyclophosphamide;   Drug: Fludarabine
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2016

  • Conditions:   HER2 Positive Breast Carcinoma;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer
    Interventions:   Drug: Cyclophosphamide;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Biological: Trastuzumab
    Sponsors:   University of Nebraska;   National Cancer Institute (NCI)
    Recruiting - verified June 2016

  • Conditions:   Acute Myelogenous Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myelogenous Leukemia;   Plasma Cell Leukemia;   Myelodysplastic Syndromes;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   B-Cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-Cell Lymphoma;   Prolymphocytic Leukemia;   Lymphoblastic Lymphoma;   Burkitt's Lymphoma;   Non-Hodgkin's Lymphoma;   Multiple Myeloma;   Myeloproliferative Syndromes;   Hematological Diseases
    Interventions:   Drug: Allopurinol;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: ATG;   Radiation: TBI;   Drug: Tacrolimus;   Drug: MMF;   Biological: Peripheral Blood Stem Cells;   Biological: Related or Unrelated Bone Marrow Cells
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Not yet recruiting - verified January 2016

  • Conditions:   Melanoma (Skin);   Skin Cancer
    Interventions:   Drug: Nivolumab;   Procedure: Surgery to Remove Tumor for Growth of TIL;   Drug: CD137;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: TIL Infusion;   Drug: Interleukin-2
    Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   Bristol-Myers Squibb;   Prometheus Inc.
    Recruiting - verified March 2016

  • Conditions:   Neuroblastoma;   High-Risk
    Interventions:   Drug: cyclophosphamide;   Biological: NK cells;   Biological: hu3F8;   Drug: rIL-2
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting - verified February 2016

  • Condition:   Lymphoma
    Interventions:   Drug: Fludarabine Phosphate;   Drug: Mesna;   Drug: Cyclophosphamide;   Radiation: Total nodal irradiation;   Biological: T Cell-Depleted Hematopoietic Stem Cell Transplantation;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Mycophenolate Mofetil;   Drug: Tacrolimus;   Biological: Rituximab
    Sponsors:   Peiman Hematti;   National Cancer Institute (NCI);   University of Wisconsin, Madison
    Recruiting - verified April 2016

  • Conditions:   Colorectal Adenocarcinoma;   Metastatic Pancreatic Adenocarcinoma;   Recurrent Breast Carcinoma;   Recurrent Colorectal Carcinoma;   Recurrent Melanoma of the Skin;   Recurrent Non-Small Cell Lung Carcinoma;   Recurrent Pancreatic Carcinoma;   Recurrent Renal Cell Carcinoma;   Solid Neoplasm;   Stage IV Breast Cancer;   Stage IV Non-Small Cell Lung Cancer;   Stage IV Renal Cell Cancer;   Stage IV Skin Melanoma;   Stage IVA Colorectal Cancer;   Stage IVA Pancreatic Cancer;   Stage IVB Colorectal Cancer;   Stage IVB Pancreatic Cancer
    Interventions:   Drug: Cyclophosphamide;   Other: Laboratory Biomarker Analysis;   Biological: Pegfilgrastim;   Other: Pharmacological Study;   Drug: TLR8 Agonist VTX-2337
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting - verified February 2016

  • Conditions:   Neutropenia;   Breast Cancer
    Interventions:   Drug: SPI-2012;   Drug: Pegfilgrastim
    Sponsor:   Spectrum Pharmaceuticals, Inc
    Recruiting - verified March 2016

  • Condition:   Adult Solid Neoplasm
    Interventions:   Drug: Cyclophosphamide;   Other: Laboratory Biomarker Analysis;   Biological: NY-ESO-1 Reactive TCR Retroviral Vector Transduced Autologous PBL;   Biological: TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
    Not yet recruiting - verified May 2016

  • Condition:   Lymphoma
    Interventions:   Drug: Rituximab;   Drug: Ibrutinib;   Drug: Lenalidomide;   Drug: Etoposide;   Drug: Prednisone;   Drug: Vincristine;   Drug: Cyclophosphamide;   Drug: Doxorubicin
    Sponsors:   M.D. Anderson Cancer Center;   Celgene;   Janssen Scientific Affairs, LLC
    Recruiting - verified March 2016

  • Conditions:   Leukemia;   Chronic Lymphocytic Leukemia
    Interventions:   Drug: Obinutuzumab;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Ibrutinib;   Drug: Allopurinol;   Drug: Valacyclovir
    Sponsors:   M.D. Anderson Cancer Center;   Genentech, Inc.;   Pharmacyclics
    Recruiting - verified June 2016

  • Condition:   X-Linked Chronic Granulomatious Disease
    Interventions:   Drug: Campath;   Drug: Busulfan;   Other: allogeneic peripheral blood allograft infusion;   Drug: cyclophosphamide
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting - verified April 2016

  • Conditions:   Inflammatory Breast Cancer;   Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
    Interventions:   Drug: Eribulin;   Drug: Adriamycin;   Drug: Cyclophosphamide
    Sponsors:   Dana-Farber Cancer Institute;   Eisai Inc.
    Recruiting - verified April 2016

  • Conditions:   Mantle Cell Lymphoma;   Untreated
    Interventions:   Drug: Lenalidomide;   Drug: R-CHOP;   Drug: high-dose cytarabine (HIDAC)
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Celgene Corporation
    Recruiting - verified April 2016

  • Conditions:   Diffuse Large B-Cell Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Transformed Recurrent Non-Hodgkin Lymphoma
    Interventions:   Drug: Carboplatin;   Drug: Etoposide;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Biological: Rituximab
    Sponsors:   Academic and Community Cancer Research United;   National Cancer Institute (NCI)
    Not yet recruiting - verified December 2015

  • Condition:   Relapsed or Refractory Acute Myeloid Leukemia
    Interventions:   Biological: Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes;   Drug: Cyclophosphamide
    Sponsor:   Abramson Cancer Center of the University of Pennsylvania
    Recruiting - verified January 2016

  • Condition:   Melanoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Aldeslaukin;   Drug: Pembrolizumab;   Biological: young TIL
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified June 2016

  • Condition:   Acute Lymphoblastic Leukemia
    Intervention:   Biological: KTE-C19
    Sponsor:   Kite Pharma, Inc.
    Recruiting - verified February 2016

  • Conditions:   Hematological Disease;   Immune Deficiencies;   Solid Tumors;   Myelofibrosis;   Multiple Myeloma;   Lymphoma
    Interventions:   Radiation: Total Body Irradiation 1200 cGy;   Drug: Fludarabine;   Drug: Pre-Stem Cell Infusion Cyclophosphamide;   Drug: Pre-Stem Cell Infusion Mesna;   Drug: Busulfan;   Drug: Melphalan;   Procedure: Stem Cell Infusion;   Drug: Post-Stem Cell Infusion Cyclophosphamide;   Drug: Post-Stem Cell Infusion Mesna
    Sponsor:   University of Rochester
    Recruiting - verified January 2016

  • Condition:   Hodgkin Lymphoma
    Intervention:   Biological: CD19 RNA redirected autologous T-cells (RNA CART19 cells)
    Sponsors:   University of Pennsylvania;   Children's Hospital of Philadelphia
    Recruiting - verified December 2015

  • Condition:   Neuroblastoma
    Interventions:   Drug: Thiotepa;   Drug: Cyclophosphamide;   Drug: Melphalan;   Drug: Etoposide;   Drug: Carboplatin;   Biological: Autologous Stem Cell Infusion;   Biological: Granulocyte colony stimulating factor
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified June 2016

  • Condition:   Acute Lymphoblastic Leukemia
    Intervention:   Biological: KTE-C19
    Sponsor:   Kite Pharma, Inc.
    Recruiting - verified March 2016

  • Condition:   Diffuse Large B-Cell Lymphoma, Lymphoma, Follicular
    Interventions:   Drug: Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody;   Drug: Bendamustine;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Obinutuzumab;   Drug: Prednisone;   Drug: Vincristine
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified June 2016

  • Condition:   Lymphoma, Non-Hodgkin
    Interventions:   Drug: Copanlisib (BAY 80-6946);   Drug: Placebo;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Bendamustine;   Drug: Prednisone
    Sponsor:   Bayer
    Recruiting - verified June 2016

  • Condition:   Breast Cancer
    Interventions:   Biological: Low dose FRα vaccine;   Drug: Cyclophosphamide;   Biological: High dose FRα vaccine
    Sponsor:   Tapimmune Inc.
    Recruiting - verified May 2016

  • Condition:   Relapsed/Refractory Mantle Cell Lymphoma
    Intervention:   Biological: KTE-C19
    Sponsor:   Kite Pharma, Inc.
    Recruiting - verified February 2016

  • Condition:   Lymphoma
    Interventions:   Drug: Duvelisib;   Drug: Rituximab;   Drug: R-CHOP;   Drug: Prednisone
    Sponsor:   Infinity Pharmaceuticals, Inc.
    Recruiting - verified February 2016

  • Conditions:   Chronic Myelogenous Leukemia;   Acute Myelogenous Leukemia;   Myelodysplastic Syndrome;   Acute Lymphocytic Leukemia;   Chronic Lymphocytic Leukemia;   Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma;   Myelofibrosis;   CMML;   Multiple Myeloma
    Interventions:   Drug: Fludarabine;   Drug: Melphalan;   Drug: Cyclophosphamide;   Procedure: peripheral blood stem cell transplant
    Sponsors:   Northside Hospital, Inc.;   Blood and Marrow Transplant Group of Georgia
    Recruiting - verified February 2016

  • Condition:   Epidermolysis Bullosa
    Interventions:   Drug: Thymoglobulin;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Radiation: Total Body Irradiation;   Procedure: Bone marrow infusion;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil;   Biological: Donor mesenchymal stem cell infusions
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified May 2016

  • Conditions:   Alveolar Rhabdomyosarcoma;   Botryoid-Type Embryonal Rhabdomyosarcoma;   Embryonal Rhabdomyosarcoma;   Rhabdomyosarcoma;   Sclerosing Rhabdomyosarcoma;   Spindle Cell Rhabdomyosarcoma;   Untreated Childhood Rhabdomyosarcoma
    Interventions:   Drug: Cyclophosphamide;   Biological: Dactinomycin;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Radiation Therapy;   Drug: Temsirolimus;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2016

  • Conditions:   Primary T-cell Immunodeficiency Disorders;   Common Variable Immunodeficiency;   Immune System Diseases;   Autoimmune Lymphoproliferative;   Lymphoproliferative Disorders
    Interventions:   Drug: Immunosuppression Only Conditioning;   Drug: Reduced Intensity Conditioning;   Drug: Myeloablative Conditioning;   Drug: GVHD Prophylaxis;   Procedure: Allo BMT
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2016

  • Condition:   Cancer
    Interventions:   Drug: Sirolimus;   Drug: Celecoxib;   Drug: Etoposide;   Drug: Cyclophosphamide
    Sponsor:   Emory University
    Recruiting - verified April 2016

  • Conditions:   Acute Myeloid Leukemia;   Acute Myeloid Leukemia in Remission;   Aplastic Anemia;   Chronic Myelomonocytic Leukemia;   Hodgkin Lymphoma;   Indolent Non-Hodgkin Lymphoma;   Malignant Neoplasm;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Plasma Cell Myeloma;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Ring Sideroblasts;   Refractory Cytopenia With Multilineage Dysplasia;   Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts
    Interventions:   Drug: Fludarabine;   Radiation: Total-Body Irradiation;   Biological: T Cell-Depleted Donor Lymphocyte Infusion;   Drug: Cyclophosphamide;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil
    Sponsor:   Thomas Jefferson University
    Recruiting - verified May 2016

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myelogenous Leukemia;   Myelodysplastic Syndrome;   Chronic Myelogenous Leukemia;   Non-Hodgkin Lymphoma;   Hodgkin Lymphoma
    Interventions:   Radiation: Radiation;   Drug: Cyclophosphamide;   Biological: Donor Lymphocyte Infusion (DLI);   Biological: Haploidentical Stem Cell Transplantation
    Sponsors:   Northwell Health;   New York Blood Center
    Recruiting - verified May 2016

  • Conditions:   Anaplastic Large Cell Lymphoma, ALK-Negative;   Anaplastic Large Cell Lymphoma, ALK-Positive;   Hepatosplenic T-Cell Lymphoma;   Peripheral T-Cell Lymphoma, Not Otherwise Specified;   Stage II Angioimmunoblastic T-cell Lymphoma;   Stage II Enteropathy-Associated T-Cell Lymphoma;   Stage III Angioimmunoblastic T-cell Lymphoma;   Stage III Enteropathy-Associated T-Cell Lymphoma;   Stage IV Angioimmunoblastic T-cell Lymphoma;   Stage IV Enteropathy-Associated T-Cell Lymphoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Vincristine Sulfate;   Drug: Etoposide;   Drug: Prednisone;   Drug: Lenalidomide;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Other: Laboratory Biomarker Analysis
    Sponsors:   University of Nebraska;   National Cancer Institute (NCI)
    Not yet recruiting - verified October 2015

  • Condition:   Peripheral T-Cell Lymphoma (PTCL)
    Intervention:   Drug: Pralatrexate Injection
    Sponsor:   Spectrum Pharmaceuticals, Inc
    Recruiting - verified November 2015

  • Conditions:   Myelodysplastic Syndrome;   Chronic Myelomonocytic Leukemia;   Small Lymphocytic Lymphoma;   Chronic Lymphocytic Leukemia;   Prolymphocytic Leukemia;   Chronic Myeloid Leukemia;   Chronic Myeloproliferative Disorders;   Multiple Myeloma;   Plasma Cell Neoplasm;   Plasma Cell Dyscrasia;   Myelofibrosis;   Polycythemia Vera;   Essential Thrombocythemia;   Plasma Cell Leukemia
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total body irradiation;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center
    Recruiting - verified June 2016

  • Condition:   Acute Lymphoblastic Leukemia
    Interventions:   Drug: ITMHA;   Drug: Dexamethasone;   Drug: Mitoxantrone;   Drug: Pegaspargase;   Drug: Asparaginase Erwinia Chrysanthemi;   Drug: Bortezomib;   Drug: Vorinostat;   Drug: Cyclophosphamide;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Leucovorin Calcium;   Drug: Cytarabine;   Drug: Etoposide;   Drug: Vincristine
    Sponsors:   St. Jude Children's Research Hospital;   Gateway for Cancer Research;   Texas Children's Hospital
    Recruiting - verified April 2016

  • Condition:   Squamous Cell Carcinoma of the Oral Cavity
    Interventions:   Biological: IRX-2;   Drug: Cyclophosphamide;   Drug: Indomethacin;   Dietary Supplement: Zinc-containing multivitamin;   Drug: Omeprazole
    Sponsor:   IRX Therapeutics
    Recruiting - verified April 2016

  • Conditions:   Cutaneous T-Cell Non-Hodgkin Lymphoma;   Recurrent Mycosis Fungoides and Sezary Syndrome;   Stage IIB Mycosis Fungoides and Sezary Syndrome;   Stage IIIA Mycosis Fungoides and Sezary Syndrome;   Stage IIIB Mycosis Fungoides and Sezary Syndrome;   Stage IVA Mycosis Fungoides and Sezary Syndrome;   Stage IVB Mycosis Fungoides and Sezary Syndrome
    Interventions:   Drug: Fludarabine;   Radiation: Total-Body Irradiation;   Biological: T Cell-Depleted Donor Lymphocyte Infusion;   Drug: Cyclophosphamide;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Mycophenolate mofetil;   Drug: Tacrolimus
    Sponsor:   Thomas Jefferson University
    Recruiting - verified April 2016

  • Conditions:   B Acute Lymphoblastic Leukemia;   B Lymphoblastic Lymphoma;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent B Lymphoblastic Lymphoma;   Recurrent T Lymphoblastic Leukemia/Lymphoma;   Refractory B Lymphoblastic Lymphoma;   Refractory T Lymphoblastic Lymphoma;   T Acute Lymphoblastic Leukemia;   T Lymphoblastic Lymphoma
    Interventions:   Drug: Asparaginase;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Imatinib Mesylate;   Other: Laboratory Biomarker Analysis;   Drug: Prednisone;   Biological: Rituximab;   Drug: Vincristine Sulfate
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Not yet recruiting - verified April 2016

  • Conditions:   Stage I Diffuse Large B-Cell Lymphoma;   Stage II Diffuse Large B-Cell Lymphoma;   Stage III Diffuse Large B-Cell Lymphoma;   Stage IV Diffuse Large B-Cell Lymphoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Drug: Prednisone;   Biological: Rituximab;   Drug: Vincristine Sulfate
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting - verified June 2016

  • Condition:   Peripheral Neuropathy
    Interventions:   Procedure: Axon Reflexes;   Procedure: Axon Flares;   Procedure: Self-Reported Signs & Symptoms of CIPN
    Sponsors:   Indiana University;   National Institute of Nursing Research (NINR);   Midwest Nursing Research Society (MNRS);   Council for the Advancement of Nursing Science (CANS);   Indiana Center for Vascular Biology & Medicine (ICVBM);   Indiana University Simon Cancer Center (IUSCC)
    Recruiting - verified March 2016

  • Conditions:   Leukemia;   Chronic Lymphocytic Leukemia
    Interventions:   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Fludarabine monophosphate;   Drug: Bendamustine;   Biological: Activated T-Cell Infusion;   Drug: Lenalidomide;   Behavioral: Phone Calls
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting - verified June 2016

  • Conditions:   Leukemia;   Lymphoma
    Interventions:   Drug: Fludarabine monophosphate;   Drug: Cyclophosphamide;   Procedure: T Cell Infusion
    Sponsors:   M.D. Anderson Cancer Center;   Ziopharm;   Intrexon Corporation
    Recruiting - verified February 2016

  • Condition:   Lymphoma
    Interventions:   Drug: Lenalidomide;   Drug: Obinutuzumab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone
    Sponsors:   M.D. Anderson Cancer Center;   Celgene;   Genentech, Inc.
    Recruiting - verified June 2016

  • Condition:   Breast Cancer
    Interventions:   Drug: Olaparib;   Drug: Carboplatin;   Drug: Anthracycline;   Drug: Cyclophosphamide
    Sponsor:   AstraZeneca
    Recruiting - verified May 2016

  • Condition:   Diffuse Large B-Cell Lymphoma
    Interventions:   Drug: Metformin;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone;   Drug: pegfilgrastim
    Sponsor:   Rush University Medical Center
    Recruiting - verified April 2016

  • Conditions:   Relapsed Solid Tumors;   Refractory Solid Tumors;   Leukemias
    Interventions:   Drug: Carfilzomib;   Drug: Cyclophosphamide;   Drug: Etoposide
    Sponsors:   Phoenix Children's Hospital;   Onyx Pharmaceuticals;   Pediatric Oncology Experimental Therapeutics Investigators' Consortium
    Recruiting - verified April 2016

  • Condition:   Breast Cancer
    Interventions:   Drug: Docetaxel;   Drug: Cyclophosphamide;   Other: Function Assessment of Cancer Therapy (FACT) Surveys
    Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   Saladax Biomedical, Inc.
    Recruiting - verified June 2016

  • Condition:   Melanoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Fludarabine;   Procedure: TIL (T-cells);   Drug: IL-2;   Drug: MK-347;   Behavioral: Questionnaires;   Behavioral: Phone Calls
    Sponsors:   M.D. Anderson Cancer Center;   Merck Sharp & Dohme Corp.
    Recruiting - verified June 2016

  • Conditions:   Acute Lymphoblastic Leukemia;   Lymphoma, Non-Hodgkin's;   Leukemia, T-Cell;   Leukemia, B-Cell
    Interventions:   Drug: Dexamethasone;   Drug: Panobinostat;   Drug: Liposomal vincristine;   Drug: Mitoxantrone;   Drug: Peg-asparaginase;   Drug: Bortezomib;   Drug: Intrathecal Triples;   Drug: High-dose methotrexate;   Drug: 6-Mercaptopurine;   Drug: High-dose cytarabine;   Drug: Nelarabine;   Drug: Cyclophosphamide;   Drug: Etoposide;   Drug: Clofarabine
    Sponsors:   St. Jude Children's Research Hospital;   Novartis Pharmaceuticals
    Recruiting - verified February 2016

  • Conditions:   High Grade Serous Ovarian Cancer;   Primary Peritoneal Cancer;   Fallopian Tube Cancer
    Interventions:   Procedure: Production of Genetically-modified T cells;   Drug: Cyclophosphamide;   Device: IP Catheter Insertion;   Genetic: Infusion of 4H11-28z/fIL-12/EFGRt+ Genetically-modified T cells
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting - verified May 2016

  • Conditions:   Breast Adenocarcinoma;   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer;   Triple-Negative Breast Carcinoma
    Interventions:   Drug: Carboplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel
    Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
    Recruiting - verified June 2016

  • Condition:   Breast Neoplasms
    Intervention:   Drug: MEDI4736
    Sponsor:   Yale University
    Recruiting - verified December 2015

  • Condition:   EWINGS SARCOMA
    Interventions:   Drug: Rabbit anti-thymocyte globulin;   Drug: Busulfan;   Drug: Melphalan;   Drug: Fludarabine;   Drug: Cyclophosphamide
    Sponsor:   University of Louisville
    Recruiting - verified May 2016

  • Conditions:   Adult Burkitt Lymphoma;   B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma;   Diffuse Large B-Cell Lymphoma;   MYC Gene Mutation;   Plasmablastic Lymphoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Ixazomib Citrate;   Other: Laboratory Biomarker Analysis;   Drug: Methotrexate;   Drug: Prednisone;   Biological: Rituximab;   Drug: Therapeutic Hydrocortisone;   Drug: Vincristine Sulfate
    Sponsors:   Northwestern University;   National Cancer Institute (NCI);   Millennium Pharmaceuticals, Inc.
    Not yet recruiting - verified August 2015

  • Condition:   Pancreatic Cancer
    Interventions:   Drug: Cyclophosphamide;   Biological: GVAX pancreatic cancer;   Drug: Nivolumab
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center
    Recruiting - verified February 2016

  • Conditions:   Adult Acute Lymphoblastic Leukemia in Complete Remission;   Acute Myeloid Leukemia in Remission;   Previously Treated Myelodysplastic Syndrome;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Childhood Acute Lymphoblastic Leukemia in Complete Remission
    Interventions:   Procedure: Bone Marrow Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Radiation: Total Marrow Irradiation
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting - verified April 2016

  • Conditions:   B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma
    Interventions:   Procedure: Autologous Bone Marrow Transplantation;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Etoposide;   Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Other: Placebo
    Sponsor:   National Cancer Institute (NCI)
    Not yet recruiting - verified May 2015

  • Conditions:   Multiple Myeloma;   Myeloma-Multiple
    Interventions:   Biological: Tocilizumab;   Drug: Melphalan;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: Filgrastim
    Sponsor:   Washington University School of Medicine
    Recruiting - verified January 2016

  • Condition:   Leukemia
    Interventions:   Drug: Busulfan;   Drug: Fludarabine;   Drug: Clofarabine;   Radiation: Total Body Irradiation (TBI);   Drug: Thymoglobulin;   Biological: Stem Cell Infusion;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: Decitabine;   Drug: Cytarabine;   Drug: Idarubicin
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting - verified March 2016

  • Condition:   Neuroblastoma
    Interventions:   Drug: cyclophosphamide;   Drug: Fludarabine;   Genetic: GINAKIT Cells
    Sponsors:   Baylor College of Medicine;   Center for Cell and Gene Therapy, Baylor College of Medicine;   Texas Children's Hospital;   Alex's Lemonade Stand Foundation
    Not yet recruiting - verified June 2016

  • Condition:   Melanoma
    Interventions:   Biological: 6MHP;   Drug: Montanide ISA-51;   Drug: polyICLC;   Drug: Cyclophosphamide
    Sponsors:   Craig L Slingluff, Jr;   Ludwig Institute for Cancer Research;   Cancer Research Institute, New York City
    Recruiting - verified April 2016

  • Condition:   Lymphoma
    Interventions:   Drug: Ibrutinib;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Dexamethasone;   Drug: Mesna;   Drug: Vincristine;   Drug: Doxorubicin;   Drug: G-CSF;   Drug: Methotrexate;   Drug: Cytarabine;   Drug: Citrovorum
    Sponsors:   M.D. Anderson Cancer Center;   Pharmacyclics
    Recruiting - verified June 2016

  • Condition:   Leukemia
    Interventions:   Drug: Ruxolitinib;   Drug: Dasatinib;   Drug: Rituximab;   Drug: G-CSF;   Drug: Pegfilgrastim;   Drug: Methotrexate;   Drug: Cytarabine;   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Dexamethasone;   Drug: Solumedrol;   Drug: 6-mercaptopurine;   Drug: Prednisone;   Drug: Leucovorin
    Sponsors:   M.D. Anderson Cancer Center;   Incyte Corporation
    Recruiting - verified February 2016

  • Conditions:   Leukemia;   Lymphoma
    Interventions:   Drug: Rituximab;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total Body Radiation;   Procedure: Fucosylated Regulatory T Cells;   Procedure: Cord Blood Transplant;   Drug: Mycophenolate mofetil;   Drug: Sirolimus;   Procedure: Bone Marrow Aspiration;   Drug: G-CSF
    Sponsors:   M.D. Anderson Cancer Center;   Miltenyi Biotec GmbH
    Recruiting - verified March 2016

  • Condition:   Advanced Cancers
    Interventions:   Drug: Selinexor;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Eribulin;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Pemetrexed;   Drug: Topotecan;   Drug: Irinotecan;   Drug: 5-FU;   Drug: Capecitabine;   Drug: Oxaliplatin;   Drug: Olaparib;   Drug: Pembrolizumab
    Sponsors:   M.D. Anderson Cancer Center;   Karyopharm Therapeutics, Inc
    Recruiting - verified April 2016

  • Conditions:   Leukemia;   Precursor-B Acute Lymphoblastic Leukemia;   Lymphoblastic Lymphoma;   Lymphoma
    Interventions:   Drug: Cytarabine;   Drug: Daunorubicin;   Drug: Vincristine;   Drug: Prednisone;   Drug: PEG asparaginase;   Drug: Ofatumumab;   Drug: Rituximab;   Drug: Methotrexate;   Drug: Cyclophosphamide;   Drug: Mercaptopurine;   Drug: Doxorubicin;   Drug: Dexamethasone acetate;   Drug: Thioguanine
    Sponsors:   M.D. Anderson Cancer Center;   Jazz Pharmaceuticals
    Recruiting - verified May 2016

  • Condition:   Triple-negative Breast Cancer
    Interventions:   Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Docetaxel
    Sponsor:   University of Kansas Medical Center
    Recruiting - verified June 2016

  • Condition:   ROHHAD Syndrome
    Intervention:   Drug: Cyclophosphamide
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center
    Recruiting - verified May 2016

  • Conditions:   Malignant Pleural Disease;   Mesothelioma;   Metastases;   Lung Cancer;   Breast Cancer
    Interventions:   Genetic: iCasp9M28z T cell infusions;   Drug: cyclophosphamide
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting - verified June 2016

  • Conditions:   Advanced Pleural Malignant Mesothelioma;   HLA-A*0201 Positive Cells Present;   Recurrent Non-Small Cell Lung Carcinoma;   Recurrent Pleural Malignant Mesothelioma;   Stage III Pleural Mesothelioma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Non-Small Cell Lung Cancer;   Stage IV Pleural Mesothelioma
    Interventions:   Biological: Aldesleukin;   Biological: Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes;   Drug: Cyclophosphamide;   Other: Laboratory Biomarker Analysis;   Procedure: Therapeutic Conventional Surgery
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified May 2016

  • Condition:   Solid Tumors
    Interventions:   Drug: Dasatinib;   Drug: Cyclophosphamide;   Drug: Temsirolimus
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting - verified April 2016

  • Conditions:   Retinoblastoma;   Clear Cell Sarcoma;   Renal Cell Carcinoma;   Rhabdoid Tumor;   Wilms Tumor;   Hepatoblastoma;   Neuroblastoma;   Germ Cell Tumors;   Ewings Sarcoma;   Non-rhabdomyosarcoma Soft Tissue Sarcoma;   Osteosarcoma;   Rhabdomyosarcoma
    Interventions:   Drug: Simvastatin;   Drug: Cyclophosphamide;   Drug: Topotecan;   Drug: Myeloid growth factor
    Sponsors:   Emory University;   Children's Healthcare of Atlanta
    Recruiting - verified April 2016

  • Condition:   Human Immunodeficiency Virus (HIV)
    Interventions:   Drug: ZFN Modified CD4+ T Cells;   Drug: Cyclophosphamide
    Sponsors:   University of Pennsylvania;   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting - verified January 2016

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Ixazomib;   Drug: Cyclophosphamide;   Drug: Dexamethasone
    Sponsors:   Ryan Stevenson;   Rhode Island Hospital;   The Miriam Hospital;   Memorial Hospital of Rhode Island
    Recruiting - verified June 2016

  • Condition:   Metastatic Melanoma
    Intervention:   Biological: Tumor Infiltrating Lymphocytes (TIL)
    Sponsor:   John Wayne Cancer Institute
    Recruiting - verified March 2016

  • Conditions:   Advanced Cancer;   Advanced Malignancies
    Interventions:   Drug: REGN2810;   Radiation: Hypofractionated radiotherapy;   Drug: Cyclophosphamide;   Drug: Docetaxel;   Drug: Carboplatin;   Drug: GM-CSF
    Sponsors:   Regeneron Pharmaceuticals;   Sanofi
    Recruiting - verified May 2016

  • Condition:   Acute Myelogenous Leukemia
    Intervention:   Biological: IL-15
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified April 2016

  • Conditions:   Leukemia;   Myelodysplastic Syndrome;   Non-Hodgkin's Lymphoma
    Intervention:   Drug: Cyclophosphamide
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting - verified February 2016

  • Conditions:   Carcinoma, Non-Small-Cell-Lung;   Non-Small Cell Lung Cancer;   Nonsmall Cell Lung Cancer
    Interventions:   Procedure: Standard of care surgery;   Procedure: Apheresis;   Drug: Cyclophosphamide;   Biological: Personalized mature dendritic cell vaccine
    Sponsor:   Washington University School of Medicine
    Not yet recruiting - verified April 2016

  • Conditions:   Acute Leukemia;   Myelodysplasia
    Interventions:   Procedure: Unmanipulated Bone Marrow Graft with Tacrolimus/Methotrexate;   Procedure: Mobilized CD34-selected Peripheral Blood Stem Cell graft;   Procedure: Unmanipulated Bone Marrow Graft with Cyclophosphamide;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Methotrexate
    Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   Blood and Marrow Transplant Clinical Trials Network;   National Cancer Institute (NCI)
    Recruiting - verified March 2016

  • Conditions:   Leukemia, Acute Lymphoblastic;   Acute Myeloid Leukemia
    Interventions:   Drug: Clofarabine;   Drug: Cyclophosphamide;   Drug: Etoposide
    Sponsors:   Medical College of Wisconsin;   American Family Children’s Hospital;   Nationwide Children's Hospital
    Recruiting - verified January 2016

  • Conditions:   Myelodysplastic Syndrome;   Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma;   Acute Leukemia;   Multiple Myeloma
    Interventions:   Biological: Rituximab;   Drug: Conditioning Chemotherapy;   Drug: TMS;   Drug: FLAG;   Drug: EPOCH-F;   Procedure: Hematopoietic Stem Cell Transplant;   Drug: Palifermin
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified March 2016

  • Conditions:   Lymphoma, Large B-Cell, Diffuse;   Lymphoma, Follicular
    Interventions:   Drug: Oral Azacitidine;   Drug: Rituximab;   Drug: cyclophosphamide;   Drug: Vincristine;   Drug: Prednisone
    Sponsor:   Celgene Corporation
    Recruiting - verified May 2016

  • Conditions:   Refractory Diffuse Large B Cell Lymphoma;   Refractory Primary Mediastinal B Cell Lymphoma;   Refractory Transformed Follicular Lymphoma
    Intervention:   Biological: KTE-C19
    Sponsor:   Kite Pharma, Inc.
    Recruiting - verified February 2016

  • Conditions:   Hematologic Malignancies;   Graft-Versus-Host Disease
    Intervention:   Biological: Activated PTCy-MILs
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center
    Recruiting - verified August 2015

  • Conditions:   AIDS-Related Burkitt Lymphoma;   AIDS-Related Diffuse Large B-cell Lymphoma;   AIDS-Related Plasmablastic Lymphoma;   AIDS-Related Primary Effusion Lymphoma;   HIV Infection
    Interventions:   Drug: Prednisone;   Biological: Rituximab;   Drug: Etoposide;   Drug: Doxorubicin Hydrochloride;   Drug: Vincristine Sulfate;   Drug: Cyclophosphamide;   Biological: Filgrastim;   Biological: Lentivirus Vector rHIV7-shI-TAR-CCR5RZ-transduced Hematopoietic Stem/Progenitor Cells
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting - verified May 2016

  • Condition:   Neoplasm
    Interventions:   Genetic: SGT-53;   Drug: Topotecan;   Drug: Cyclophosphamide
    Sponsor:   SynerGene Therapeutics, Inc.
    Recruiting - verified May 2016

  • Conditions:   Metastatic Ewing Sarcoma;   Metastatic Malignant Neoplasm in the Bone;   Metastatic Malignant Neoplasm in the Bone Marrow;   Metastatic Malignant Neoplasm in the Lung;   Metastatic Peripheral Primitive Neuroectodermal Tumor of Bone;   Peripheral Primitive Neuroectodermal Tumor of Soft Tissues
    Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Radiation: External Beam Radiation Therapy;   Biological: Ganitumab;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Radiation: Stereotactic Radiosurgery;   Procedure: Therapeutic Surgical Procedure;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified December 2015

  • Conditions:   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Untreated Adult Acute Lymphoblastic Leukemia
    Interventions:   Drug: carfilzomib;   Drug: cyclophosphamide;   Drug: vincristine sulfate;   Drug: doxorubicin hydrochloride;   Drug: dexamethasone;   Drug: methotrexate;   Drug: cytarabine;   Drug: leucovorin calcium;   Drug: methylprednisolone;   Biological: rituximab;   Other: laboratory biomarker analysis
    Sponsors:   University of California, Davis;   Onyx Pharmaceuticals
    Recruiting - verified January 2016

  • Condition:   Lymphoma, Large B-Cell, Diffuse
    Interventions:   Drug: lenalidomide;   Drug: Placebo;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: prednisone;   Drug: vincristine
    Sponsor:   Celgene Corporation
    Recruiting - verified June 2016

  • Conditions:   Hodgkin Disease;   Non-Hodgkin Lymphoma;   Severe Chronic Active Epstein Barr Virus;   T/NK-lymphoproliferative Disease
    Interventions:   Biological: MABEL CTLs;   Drug: Cyclophosphamide;   Drug: Fludarabine
    Sponsors:   Baylor College of Medicine;   Center for Cell and Gene Therapy, Baylor College of Medicine;   Texas Children's Hospital;   The Methodist Hospital System
    Recruiting - verified March 2016

  • Condition:   Chronic Granulomatous Disease
    Interventions:   Drug: Pre-Transplant Conditioning Medications;   Other: Haploidentical Cellular Infusion;   Drug: Post-Trasnplant Medications;   Radiation: Total Body Irradiation
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting - verified May 2016

  • Condition:   Leukemia
    Interventions:   Drug: Lenalidomide;   Drug: Rituximab;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Procedure: NK Cells
    Sponsors:   M.D. Anderson Cancer Center;   The Leukemia and Lymphoma Society;   Celgene Corporation
    Recruiting - verified June 2016

  • Condition:   Adverse Drug Reaction
    Intervention:   Device: Pharmacogenetic Intervention Arm (pharmacogenetic testing)
    Sponsors:   Indiana University;   National Human Genome Research Institute (NHGRI)
    Recruiting - verified February 2016

  • Condition:   Lupus Nephritis
    Interventions:   Biological: Rituximab;   Drug: Cyclophosphamide;   Drug: Prednisone;   Drug: Methylprednisolone;   Drug: Diphenhydramine;   Drug: Acetaminophen;   Biological: Rituximab;   Drug: Cyclophosphamide;   Drug: Prednisone;   Drug: Methylprednisolone;   Drug: Diphenhydramine;   Drug: Acetaminophen;   Biological: Belimumab
    Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Immune Tolerance Network (ITN)
    Recruiting - verified February 2016

  • Conditions:   Leukemia;   Lymphoma;   Myelodysplasia
    Intervention:   Device: Alpha Beta T cell depletion
    Sponsor:   Children's Hospital of Philadelphia
    Recruiting - verified April 2016

  • Conditions:   Chronic Lymphocytic Leukemia;   Leukemia
    Interventions:   Drug: Ibrutinib;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Rituximab
    Sponsors:   Dana-Farber Cancer Institute;   Pharmacyclics
    Recruiting - verified April 2016

  • Conditions:   Graft Versus Host Disease;   Hematopoietic/Lymphoid Cancer
    Interventions:   Drug: fludarabine phosphate;   Drug: busulfan;   Drug: cyclophosphamide;   Procedure: allogeneic hematopoietic stem cell transplantation;   Drug: tacrolimus;   Drug: mycophenolate mofetil
    Sponsors:   Comprehensive Cancer Center of Wake Forest University;   National Cancer Institute (NCI)
    Recruiting - verified July 2015

  • Condition:   Previously Treated Metastatic Adenocarcinoma of the Pancreas
    Interventions:   Biological: CRS-207;   Biological: GVAX;   Drug: nivolumab;   Drug: CY
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Bristol-Myers Squibb;   Stand Up To Cancer;   Aduro BioTech;   American Association for Cancer Research
    Recruiting - verified June 2016

  • Conditions:   Primary Myelofibrosis;   Secondary Myelofibrosis
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Methotrexate;   Drug: Momelotinib;   Drug: Mycophenolate Mofetil;   Drug: Pacritinib;   Drug: Ruxolitinib;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified April 2016

  • Condition:   Neuroblastoma
    Interventions:   Drug: Sorafenib;   Drug: Cyclophosphamide;   Drug: Topotecan
    Sponsors:   New Approaches to Neuroblastoma Therapy Consortium;   University of California, San Francisco;   Children's Hospital Los Angeles;   Lucile Packard Children's Hospital;   Children's Hospital Medical Center, Cincinnati;   University of Michigan;   Seattle Children's Hospital;   Dana-Farber Cancer Institute;   The Hospital for Sick Children;   Children's Healthcare of Atlanta;   University of Chicago;   Cook Children's Health Care System;   Memorial Sloan Kettering Cancer Center;   Children's Hospital Colorado
    Recruiting - verified December 2015

  • Conditions:   Acute Lymphoblastic Leukemia;   Lymphoblastic Lymphoma;   B-cell Adult Acute Lymphoblastic Leukemia;   T-cell Adult Acute Lymphoblastic Leukemia
    Interventions:   Drug: MLN 9708;   Drug: Vincristine;   Drug: Cytarabine;   Drug: Doxorubicin;   Drug: Mercaptopurine;   Drug: Cyclophosphamide;   Drug: Methotrexate
    Sponsors:   Massachusetts General Hospital;   Millennium Pharmaceuticals, Inc.
    Recruiting - verified April 2016

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Biphenotypic Leukemia;   Acute Leukemia of Ambiguous Lineage;   Acute Undifferentiated Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Graft Versus Host Disease;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Refractory Anemia With Excess Blasts
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Methotrexate;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Drug: Thiotepa;   Radiation: Total-Body Irradiation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified May 2016

  • Conditions:   Severe Aplastic Anemia;   Bone Marrow Failure Syndromes
    Interventions:   Procedure: Bone marrow transplant;   Drug: Thymoglobulin;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: TBI;   Drug: Mesna;   Drug: Tacrolimus;   Drug: Mycophenolic acid mofetil
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center
    Recruiting - verified May 2016

  • Conditions:   Recurrent Adult Hodgkin Lymphoma;   Refractory Hodgkin Lymphoma
    Interventions:   Drug: Brentuximab Vedotin;   Drug: Carboplatin;   Drug: Etoposide;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting - verified January 2016

  • Conditions:   Melanoma;   Sarcoma
    Interventions:   Drug: Ipilimumab;   Drug: Cyclophosphamide;   Biological: CD4+ T cells
    Sponsors:   M.D. Anderson Cancer Center;   National Institutes of Health (NIH);   National Cancer Institute (NCI)
    Not yet recruiting - verified February 2016

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Melphalan;   Drug: Prednisone;   Drug: Cyclophosphamide;   Drug: Dexamethasone;   Dietary Supplement: Ascorbic acid;   Drug: PLD;   Drug: Lenalidomide
    Sponsors:   Oncotherapeutics;   Millennium: The Takeda Oncology Company
    Recruiting - verified March 2016

  • Conditions:   Adult Grade III Lymphomatoid Granulomatosis;   B-cell Chronic Lymphocytic Leukemia;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   Contiguous Stage II Marginal Zone Lymphoma;   Contiguous Stage II Small Lymphocytic Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Progressive Hairy Cell Leukemia, Initial Treatment;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage 0 Chronic Lymphocytic Leukemia;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Diffuse Small Cleaved Cell Lymphoma;   Stage I Adult Hodgkin Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Marginal Zone Lymphoma;   Stage I Small Lymphocytic Lymphoma;   Stage II Adult Hodgkin Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Small Lymphocytic Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Small Lymphocytic Lymphoma;   Testicular Lymphoma;   Untreated Hairy Cell Leukemia;   Waldenström Macroglobulinemia
    Interventions:   Drug: lenalidomide;   Drug: etoposide;   Drug: prednisone;   Drug: vincristine sulfate;   Drug: doxorubicin hydrochloride;   Drug: cyclophosphamide;   Biological: rituximab;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
    Sponsors:   University of Chicago;   National Cancer Institute (NCI)
    Recruiting - verified March 2016

  • Conditions:   Acute Myelogenous Leukemia;   Myelodysplastic Syndrome
    Intervention:   Drug: Gemtuzumab Ozogamicin
    Sponsor:   New York Medical College
    Recruiting - verified March 2016

  • Condition:   Crohn's Disease
    Intervention:   Other: Hematopoietic stem cell transplantation
    Sponsor:   TriStar Health
    Recruiting - verified March 2016

  • Condition:   Leukemia
    Interventions:   Drug: Ofatumumab;   Drug: Etoposide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Cyclophosphamide;   Drug: Prednisone;   Drug: Rituximab;   Drug: Pegfilgrastim;   Drug: G-CSF;   Behavioral: Phone Calls
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting - verified April 2016

  • Conditions:   Hematologic Neoplasms;   Graft-Versus-Host Disease
    Intervention:   Device: Alpha-beta depleted T-cell infusion after post-transplant cyclophosphamide.
    Sponsor:   Ayman Saad
    Recruiting - verified December 2015

  • Condition:   Medulloblastoma
    Interventions:   Drug: Lomustine;   Drug: Vincristine;   Drug: Cisplatin;   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Vincristine
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center
    Recruiting - verified April 2016

  • Condition:   Hematological Malignancies
    Interventions:   Drug: Cyclophosphamide;   Drug: Thiotepa;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Mesna;   Biological: G-CSF;   Drug: Mycophenolate mofetil;   Drug: Tacrolimus;   Drug: Methylprednisolone;   Radiation: Total lymphoid irradiation;   Biological: Lymphocyte infusions
    Sponsors:   St. Jude Children's Research Hospital;   Assisi Foundation
    Recruiting - verified March 2016

  • Conditions:   Recurrent Diffuse Large B-Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma
    Interventions:   Drug: Carboplatin;   Drug: Etoposide;   Drug: Ibrutinib;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Biological: Rituximab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2016

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myelogenous Leukemia;   Myelodysplastic Syndromes;   Myelofibrosis;   Relapsed Non-Hodgkin Lymphoma;   Refractory Non-Hodgkin Lymphoma;   Hodgkin Lymphoma;   Refractory Hodgkin Lymphoma;   Relapsed Chronic Lymphocytic Leukemia;   Refractory Chronic Lymphocytic Leukemia;   Lymphoid Malignancies;   Chronic Myelogenous Leukemia
    Interventions:   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Radiation: total-body irradiation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation;   Procedure: mesenchymal stem cell transplantation
    Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified March 2016

  • Condition:   Multiple Myeloma
    Intervention:   Drug: MV-NIS
    Sponsor:   University of Arkansas
    Recruiting - verified March 2016

  • Conditions:   Ganglioneuroblastoma;   Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Recurrent Neuroblastoma;   Regional Neuroblastoma;   Stage 4 Neuroblastoma
    Interventions:   Other: Clinical Observation;   Drug: Carboplatin;   Drug: Etoposide;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified March 2016

  • Conditions:   Multiple Myeloma in Relapse;   Multiple Myeloma, Refractory
    Interventions:   Drug: Pomalidomide;   Drug: Cyclophosphamide;   Drug: Dexamethasone
    Sponsors:   Ajai Chari;   Celgene Corporation
    Recruiting - verified January 2016

  • Conditions:   Adult Fibrosarcoma;   Alveolar Soft Part Sarcoma;   Angiomatoid Fibrous Histiocytoma;   Atypical Fibroxanthoma;   Clear Cell Sarcoma of Soft Tissue;   Epithelioid Malignant Peripheral Nerve Sheath Tumor;   Epithelioid Sarcoma;   Extraskeletal Myxoid Chondrosarcoma;   Extraskeletal Osteosarcoma;   Fibrohistiocytic Neoplasm;   Glomus Tumor of the Skin;   Inflammatory Myofibroblastic Tumor;   Intimal Sarcoma;   Leiomyosarcoma;   Liposarcoma;   Low Grade Fibromyxoid Sarcoma;   Low Grade Myofibroblastic Sarcoma;   Malignant Cutaneous Granular Cell Tumor;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Triton Tumor;   Mesenchymal Chondrosarcoma;   Myxofibrosarcoma;   Myxoid Chondrosarcoma;   Myxoinflammatory Fibroblastic Sarcoma;   Nerve Sheath Neoplasm;   PEComa;   Pericytic Neoplasm;   Plexiform Fibrohistiocytic Tumor;   Sclerosing Epithelioid Fibrosarcoma;   Stage IB Soft Tissue Sarcoma;   Stage IIB Soft Tissue Sarcoma;   Stage III Soft Tissue Sarcoma;   Stage IV Soft Tissue Sarcoma;   Synovial Sarcoma;   Undifferentiated (Embryonal) Sarcoma;   Undifferentiated High Grade Pleomorphic Sarcoma of Bone
    Interventions:   Drug: Doxorubicin Hydrochloride;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Drug: Pazopanib Hydrochloride;   Other: Pharmacological Study;   Radiation: Radiation Therapy;   Procedure: Therapeutic Conventional Surgery
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified April 2016

  • Conditions:   Sickle Cell Disease;   Thalassemia;   Diamond Blackfan Anemia;   Non-malignant Hematologic Disorders
    Interventions:   Drug: Anti-thymocyte globulin (ATG);   Drug: Fludarabine monophosphate;   Drug: Busulfan;   Drug: Alemtuzumab;   Drug: Cyclophosphamide;   Drug: Fludarabine monophosphate;   Drug: Mesna;   Radiation: total body irradiation
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified January 2016

  • Conditions:   Classical Hodgkin Lymphoma;   Stage IIB Hodgkin Lymphoma;   Stage IIIB Hodgkin Lymphoma;   Stage IVA Hodgkin Lymphoma;   Stage IVB Hodgkin Lymphoma
    Interventions:   Biological: Bleomycin Sulfate;   Drug: Brentuximab Vedotin;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Prednisone;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified February 2016

  • Condition:   Multiple Myeloma
    Interventions:   Drug: POM;   Drug: Steroids;   Drug: PLD;   Drug: CFZ;   Drug: BTZ;   Drug: CLA;   Drug: Other drugs
    Sponsors:   Oncotherapeutics;   Celgene Corporation
    Recruiting - verified March 2016

  • Conditions:   Mucopolysaccharidosis I;   Mucopolysaccharidosis II;   Mucopolysaccharidosis VI;   Mucopolysaccharidosis VII;   Hurler Syndrome;   Hunter Syndrome;   Maroteaux Lamy Syndrome;   Sly Syndrome;   Glycoprotein Metabolic Disorders;   Alpha Mannosidosis;   Fucosidosis;   Aspartylglucosaminuria;   Adrenoleukodystrophy;   Peroxisomal Disorders;   Osteopetrosis;   Sphingolipidosis;   Gangliosidosis;   Globoid Cell Leukodystrophy;   Metachromatic Leukodystrophy;   Niemann Pick B;   Niemann Pick C Subtype 2;   I-cell Disease
    Interventions:   Procedure: blood stem cell transplant;   Drug: Rabbit Anti-Thymocyte Globulin (ATG);   Drug: Fludarabine;   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Cyclosporine A (CSA);   Drug: Methylprednisolone;   Drug: Mycophenolate Mofetil (MMF);   Drug: Granulocyte-Colony Stimulating Factor (G-CSF);   Drug: Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF);   Drug: N-acetylcysteine;   Drug: Celecoxib;   Drug: Vitamin E;   Drug: Alpha Lipoic Acid
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified January 2016

  • Conditions:   Leukemia;   MDS;   Myelofibrosis;   Lymphoma
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Mesna;   Radiation: Total Body Irradiation;   Other: Hematopoietic stem cell infusion;   Drug: Tacrolimus;   Drug: Mycophenolate;   Drug: G-CSF
    Sponsor:   University of Pittsburgh
    Recruiting - verified January 2016

  • Conditions:   Dyskeratosis Congenita;   Aplastic Anemia
    Interventions:   Drug: Alemtuzumab;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation;   Biological: Stem Cell Transplant;   Drug: Anti-thymocyte globulin
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified January 2016

  • Conditions:   Primary Graft Failure;   Secondary Graft Failure
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation;   Biological: Hematopoietic stem cell infusion
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified January 2016

  • Condition:   Chronic Lymphocytic Leukemia
    Interventions:   Drug: IPI-145;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Rituximab
    Sponsors:   Dana-Farber Cancer Institute;   Infinity Pharmaceuticals, Inc.
    Recruiting - verified August 2015

  • Conditions:   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Recurrent Adult Acute Myeloid Leukemia
    Interventions:   Drug: cyclophosphamide;   Biological: anti CD123-CAR/CD28-costimulatory, lentiviral vector-transduced autologous T lymphocytes;   Other: laboratory biomarker analysis;   Drug: Etoposide;   Drug: Fludarabine Phosphate;   Biological: Therapeutic Allogeneic Lymphocytes
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting - verified February 2016

  • Conditions:   Acute Leukemia;   Chronic Leukemia;   Myelodysplastic Syndrome;   Lymphomas;   Multiple Myeloma
    Intervention:   Drug: MLN9708
    Sponsors:   Northside Hospital, Inc.;   Millennium Pharmaceuticals, Inc.
    Recruiting - verified February 2016

  • Conditions:   Acute Leukemias;   Burkitt's Lymphoma;   Chronic Myelogenous Leukemia
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation;   Biological: Haploidentical stem cell transplant
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified January 2016

  • Condition:   Breast Cancer
    Interventions:   Drug: 5-fluorouracil;   Drug: cyclophosphamide;   Drug: cyclophosphamide;   Drug: docetaxel;   Drug: doxorubicin;   Drug: epirubicin;   Drug: paclitaxel;   Drug: pertuzumab [Perjeta];   Drug: trastuzumab [Herceptin]
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified June 2016

  • Conditions:   Diffuse Large B Cell Lymphoma Relapsed;   Diffuse Large B Cell Lymphoma Refractory
    Interventions:   Drug: Ibrutinib, DA-EPOCH-R;   Drug: Ibrutinib, Lenalidomide, DA-EPOCH-R
    Sponsors:   Pharmacyclics;   Celgene Corporation
    Recruiting - verified March 2016

  • Conditions:   Metastatic Non-Small Cell Lung Cancer;   Squamous Cell Carcinoma;   Advanced NSCLC;   Adenosquamous Carcinoma;   Adenocarcinomas
    Interventions:   Drug: Aldesleukin;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Biological: Young TIL
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified June 2016

  • Conditions:   Fanconi Anemia;   Severe Marrow Failure;   Myelodysplastic Syndrome (MDS);   Acute Myelogenous Leukemia (AML)
    Interventions:   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: rabbit ATG;   Drug: G-CSF;   Biological: Peripheral blood stem cell
    Sponsors:   Children's Hospital Medical Center, Cincinnati;   Memorial Sloan Kettering Cancer Center
    Recruiting - verified December 2015

  • Condition:   Multiple Myeloma
    Intervention:   Drug: MEL-CFZ-TD-PACE
    Sponsors:   University of Arkansas;   Onyx Pharmaceuticals
    Recruiting - verified March 2016

  • Conditions:   Myeloablative Conditioning;   HLA-mismatched Bone Marrow Transplantation;   Graft Survival;   Transplantion, Bone Marrow
    Interventions:   Drug: Cyclophosphamide;   Radiation: TBI;   Drug: Busulfan;   Other: Unmanipulated Bone Marrow;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center
    Recruiting - verified May 2016

  • Conditions:   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Adult Acute Myeloid Leukemia
    Interventions:   Radiation: radiation therapy;   Drug: cyclophosphamide;   Biological: anti-thymocyte globulin;   Drug: tacrolimus;   Drug: methotrexate;   Procedure: allogeneic bone marrow transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Other: laboratory biomarker analysis
    Sponsor:   Ohio State University Comprehensive Cancer Center
    Recruiting - verified January 2016

  • Conditions:   Malignant Rhabdoid Tumor;   Atypical Teratoid Rhabdoid Tumor
    Interventions:   Drug: alisertib;   Drug: methotrexate;   Drug: cisplatin;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: topotecan;   Drug: vincristine;   Procedure: Surgical resection;   Radiation: Radiation therapy
    Sponsors:   St. Jude Children's Research Hospital;   Millennium Pharmaceuticals, Inc.
    Recruiting - verified May 2016

  • Conditions:   Adult T Acute Lymphoblastic Leukemia;   Childhood T Acute Lymphoblastic Leukemia;   Stage II Childhood Lymphoblastic Lymphoma;   Stage II Contiguous Adult Lymphoblastic Lymphoma;   Stage II Non-Contiguous Adult Lymphoblastic Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
    Interventions:   Drug: Bortezomib;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Hydrocortisone Sodium Succinate;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Radiation: Radiation Therapy;   Drug: Thioguanine;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified June 2016

  • Conditions:   B Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Asparaginase;   Biological: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Mitoxantrone Hydrochloride;   Drug: Pegaspargase;   Other: Pharmacological Study;   Drug: Therapeutic Hydrocortisone;   Drug: Thioguanine;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified March 2016

  • Conditions:   Sarcoma;   Osteosarcoma;   Neuroblastoma;   Melanoma
    Interventions:   Biological: Anti-GD2-CAR engineered T cells;   Drug: AP1903;   Drug: Cyclophosphamide
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified April 2016

  • Conditions:   Sickle Cell Disease;   Thalassemia;   Stem Cell Transplantation;   Graft vs Host Disease
    Interventions:   Drug: Alemtuzumab;   Drug: Sirolimus;   Drug: Cyclophosphamide;   Drug: Pentostatin;   Drug: Radiotherapy
    Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI);   National Institutes of Health Clinical Center (CC)
    Recruiting - verified March 2016

  • Conditions:   Ovarian Cancer;   Fallopian Tube Carcinoma;   Primary Peritoneal Carcinoma
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Biological: NK cells;   Biological: IL-2;   Drug: INCB024360
    Sponsors:   Masonic Cancer Center, University of Minnesota;   Incyte Corporation
    Recruiting - verified January 2016

  • Conditions:   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia
    Interventions:   Drug: etoposide;   Drug: cyclophosphamide;   Radiation: total marrow irradiation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: allogeneic bone marrow transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: fludeoxyglucose F 18;   Procedure: positron emission tomography;   Procedure: computed tomography
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting - verified April 2016

  • Conditions:   Breast Cancer;   Stage I Breast Cancer;   Stage II Breast Cancer;   Stage III Breast Cancer
    Interventions:   Drug: Simvastatin;   Drug: Doxorubicin/cyclophosphamide
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center
    Recruiting - verified January 2016

  • Condition:   Hematologic Malignancies
    Intervention:   Drug: Cyclophosphamide
    Sponsor:   Dartmouth-Hitchcock Medical Center
    Recruiting - verified February 2016

  • Conditions:   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma
    Interventions:   Drug: carfilzomib;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: vincristine sulfate;   Drug: prednisone;   Other: laboratory biomarker analysis
    Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified May 2016

  • Condition:   Unspecified Adult Solid Tumor, Protocol Specific
    Interventions:   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Biological: NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL;   Biological: dendritic cell vaccine therapy;   Biological: aldesleukin;   Radiation: fludeoxyglucose F 18;   Procedure: positron emission tomography;   Other: laboratory biomarker analysis
    Sponsors:   Jonsson Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified March 2016

  • Condition:   EBV-positive Nasopharyngeal Carcinoma
    Interventions:   Genetic: DNR.NPC-specific T cells;   Genetic: DNR.NPC-specific T cells + cyclophosphamide + fludarabine
    Sponsors:   Baylor College of Medicine;   National Cancer Institute (NCI);   Center for Cell and Gene Therapy, Baylor College of Medicine;   The Methodist Hospital System;   Texas Children's Hospital
    Recruiting - verified June 2016

  • Condition:   Leukemia, Myeloid, Acute
    Interventions:   Drug: busulfan;   Drug: fludarabine phosphate;   Radiation: total-body irradiation (TBI);   Procedure: Stem cell transplant;   Drug: cyclophosphamide;   Drug: tocilizumab
    Sponsor:   Washington University School of Medicine
    Recruiting - verified April 2016

  • Condition:   Non-Hodgkin's Lymphoma
    Interventions:   Drug: CHOP;   Drug: GDC-0199;   Drug: obinutuzumab;   Drug: rituximab [MabThera/Rituxan]
    Sponsors:   Hoffmann-La Roche;   AbbVie
    Recruiting - verified June 2016

  • Conditions:   Acute Lymphocytic Leukemia;   Adult Lymphoblastic Lymphoma
    Interventions:   Drug: DNR;   Drug: VCR;   Drug: PEG-asp;   Drug: CTX;   Drug: Prednisone;   Drug: Liposomal AraC;   Drug: MTX;   Drug: LCV;   Drug: AraC;   Drug: Etoposide;   Drug: Dasatinib;   Drug: Rituximab;   Drug: Hydrocortisone
    Sponsors:   University of California, San Diego;   Sigma Tau Pharmaceuticals, Inc.
    Recruiting - verified January 2016

  • Conditions:   Stage IIB Adult Soft Tissue Sarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage IV Adult Soft Tissue Sarcoma
    Interventions:   Drug: Epirubicin Hydrochloride;   Radiation: External Beam Radiation Therapy;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Drug: Sorafenib Tosylate;   Procedure: Therapeutic Conventional Surgery
    Sponsors:   OHSU Knight Cancer Institute;   Bayer;   National Cancer Institute (NCI)
    Recruiting - verified December 2015

  • Condition:   Neuroblastoma
    Interventions:   Drug: DFMO;   Drug: Celecoxib;   Drug: Cyclophosphamide;   Drug: Topotecan
    Sponsors:   New Approaches to Neuroblastoma Therapy Consortium;   National Cancer Institute (NCI)
    Recruiting - verified December 2015

  • Condition:   Melanoma
    Interventions:   Drug: Cyclophosphamide;   Procedure: CD8+ T Cells;   Drug: Interleukin-2;   Drug: Ipilimumab
    Sponsors:   M.D. Anderson Cancer Center;   Cancer Prevention Research Institute of Texas;   American Association for Cancer Research
    Recruiting - verified March 2016

  • Condition:   Kidney Transplantation
    Interventions:   Biological: Antithymocyte globulin (ATG);   Drug: Fludarabine;   Drug: Low dose Pre-transplant cyclophosphamide;   Radiation: Total Body Irradiation;   Drug: Acetaminophen;   Drug: Diphenhydramine;   Drug: Methylprednisolone;   Biological: Bone Marrow;   Drug: MESNA;   Drug: Mycophenolate mofetil (MMF);   Drug: Prednisone;   Drug: Filgrastim;   Drug: High dose post-transplant cyclophosphamide
    Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Immune Tolerance Network (ITN)
    Recruiting - verified May 2016

  • Condition:   Untreated Childhood Medulloblastoma
    Interventions:   Drug: Vincristine Sulfate;   Drug: Cyclophosphamide;   Drug: Methotrexate;   Drug: Etoposide;   Drug: Carboplatin;   Other: Laboratory Biomarker Analysis;   Other: Cognitive Assessment
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified December 2015

  • Condition:   Sickle Cell Disease
    Interventions:   Procedure: Haploidentical Transplant;   Drug: Alemtuzumab;   Radiation: Total Body Irradiation;   Drug: Cyclophosphamide;   Drug: Sirolimus
    Sponsor:   Damiano Rondelli, MD
    Recruiting - verified April 2016

  • Conditions:   Adult B Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Biological: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Prednisone;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified December 2015

  • Condition:   Breast Cancer
    Interventions:   Biological: LA TNBC: DC vaccine+Preop chemo;   Biological: ER+/HER2-BC:DC vaccine+Preop chemo
    Sponsor:   Baylor Research Institute
    Recruiting - verified January 2016

  • Condition:   Metastatic Melanoma
    Interventions:   Drug: Aldesleukin;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Biological: Young Tumor Infiltrating Lymphocytes (Young TIL);   Drug: Keytruda (pembrolizumab) - ONLY FOR RETREATMENT
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified June 2016

  • Conditions:   Stage II Childhood Anaplastic Large Cell Lymphoma;   Stage III Childhood Anaplastic Large Cell Lymphoma;   Stage IV Childhood Anaplastic Large Cell Lymphoma
    Interventions:   Drug: Brentuximab Vedotin;   Drug: Crizotinib;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Drug: Methotrexate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified December 2015

  • Condition:   Hematopoietic/Lymphoid Cancer
    Interventions:   Radiation: Total-Body Irradiation (TBI);   Biological: Donor Lymphocyte Infusion (DLI);   Drug: Cyclophosphamide;   Procedure: Allogeneic hematopoietic stem cell transplantation (HSCT);   Drug: Mycophenolate mofetil
    Sponsor:   Thomas Jefferson University
    Recruiting - verified May 2016

  • Conditions:   Leukemia;   Lymphoma;   Myelodysplastic Syndrome;   Myelofibrosis;   Severe Aplastic Anemia;   Allogeneic Transplant
    Intervention:   Drug: Cyclophosphamide
    Sponsor:   Racquel Innis-Shelton, MD
    Recruiting - verified March 2016

  • Condition:   Lymphoma, B-Cell, Non-Hodgkin's Lymphoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Obinutuzumab;   Drug: Polatuzumab Vedotin;   Drug: Prednisone/Prednisolone;   Drug: Rituximab
    Sponsor:   Genentech, Inc.
    Recruiting - verified September 2015

  • Condition:   Metastatic Colorectal Cancer
    Interventions:   Drug: CY;   Biological: GVAX;   Drug: SGI-110
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center
    Recruiting - verified June 2016

  • Conditions:   Acute Myeloid Leukemia (AML);   Acute Lymphocytic Leukemia (ALL);   Chronic Myelogenous Leukemia;   Plasma Cell Leukemia;   Myelofibrosis;   Myelodysplasia;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Marginal Zone B-Cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-Cell Lymphoma;   Prolymphocytic Leukemia;   Diffuse Large B Cell Lymphoma;   Lymphoblastic Lymphoma;   Burkitt's Lymphoma;   Non-Hodgkin Lymphoma;   Multiple Myeloma
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation;   Drug: Cyclosporine A;   Drug: Mycophenylate mofetil;   Biological: Umbilical cord blood
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Not yet recruiting - verified January 2016

  • Conditions:   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
    Interventions:   Drug: Cyclophosphamide;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Drug: Smac Mimetic LCL161
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting - verified November 2015

  • Condition:   Melanoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Fludarabine monophosphate;   Biological: T-Cells;   Drug: Interleukin-2 (IL-2);   Behavioral: Questionnaires
    Sponsors:   M.D. Anderson Cancer Center;   Cancer Prevention Research Institute of Texas
    Recruiting - verified February 2016

  • Conditions:   Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Cancer;   Stage IV Renal Cell Cancer
    Interventions:   Radiation: stereotactic body radiation therapy;   Drug: cyclophosphamide;   Biological: therapeutic autologous lymphocytes;   Other: laboratory biomarker analysis
    Sponsors:   Stanford University;   National Cancer Institute (NCI)
    Recruiting - verified April 2016

  • Conditions:   Acute Leukemias of Ambiguous Lineage;   B-cell Adult Acute Lymphoblastic Leukemia;   Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma
    Interventions:   Drug: cyclophosphamide;   Drug: vincristine sulfate;   Drug: prednisone;   Biological: inotuzumab ozogamicin;   Other: laboratory biomarker analysis
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified April 2016

  • Conditions:   Lymphoma, B-cell;   Lymphoma, Large B-cell, Diffuse
    Interventions:   Drug: brentuximab vedotin;   Drug: brentuximab vedotin;   Drug: rituximab;   Drug: vincristine;   Drug: cyclophosphamide;   Drug: prednisone;   Drug: doxorubicin
    Sponsor:   Seattle Genetics, Inc.
    Recruiting - verified May 2016

  • Conditions:   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
    Interventions:   Biological: trastuzumab;   Biological: Pertuzumab;   Drug: docetaxel;   Drug: carboplatin;   Drug: doxorubicin;   Drug: cyclophosphamide;   Drug: paclitaxel;   Other: laboratory biomarker analysis;   Other: pharmacogenomic studies;   Drug: Bevacizumab
    Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified February 2016

  • Conditions:   Breast Cancer;   Adenocarcinoma of the Breast
    Interventions:   Radiation: PBI;   Other: PBI with chemotherapy
    Sponsor:   Richard Zellars
    Recruiting - verified December 2015

  • Condition:   Leukemia
    Interventions:   Drug: Daunorubicin;   Drug: Vincristine;   Drug: Prednisone;   Drug: PEG-Asparaginase;   Drug: Methotrexate;   Drug: 6-MP (6-Mercaptopurine);   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Leucovorin;   Drug: Dexamethasone
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Sigma-Tau Research, Inc.;   Duke University;   Weill Medical College of Cornell University;   Lehigh Valley Health Network
    Recruiting - verified June 2016

  • Conditions:   Stage II Childhood Hodgkin Lymphoma;   Stage III Childhood Hodgkin Lymphoma;   Stage IV Childhood Hodgkin Lymphoma
    Interventions:   Drug: brentuximab vedotin;   Drug: etoposide;   Drug: prednisone;   Drug: doxorubicin;   Drug: cyclophosphamide;   Drug: Dacarbazine(R);   Drug: filgrastim;   Other: quality of life assessment;   Radiation: radiation therapy
    Sponsors:   St. Jude Children's Research Hospital;   Seattle Genetics, Inc.
    Recruiting - verified March 2016

  • Conditions:   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
    Interventions:   Drug: Cyclophosphamide;   Other: Cytology Specimen Collection Procedure;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Biological: Trastuzumab
    Sponsors:   Albert Einstein College of Medicine of Yeshiva University;   National Cancer Institute (NCI)
    Recruiting - verified January 2016

  • Condition:   Leukemia, Myeloid, Acute
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Procedure: Leukapheresis;   Biological: Cytokine-induced killer cells;   Biological: Aldesleukin
    Sponsor:   Washington University School of Medicine
    Recruiting - verified June 2016

  • Condition:   Medulloblastoma
    Interventions:   Radiation: Craniospinal Irradiation with boost to the primary tumor site;   Drug: Cyclophosphamide;   Drug: Cisplatin;   Drug: Vincristine;   Drug: Vismodegib;   Drug: Pemetrexed;   Drug: Gemcitabine;   Other: Aerobic Training;   Other: Neurocognitive Remediation
    Sponsors:   St. Jude Children's Research Hospital;   Genentech, Inc.;   National Cancer Institute (NCI)
    Recruiting - verified June 2016

  • Condition:   Rhabdomyosarcoma
    Interventions:   Drug: Vincristine;   Drug: Dactinomycin;   Drug: Cyclophosphamide;   Procedure: Surgical Resection;   Procedure: Radiation;   Drug: Bevacizumab;   Drug: Sorafenib;   Drug: Myeloid Growth Factor;   Procedure: Lymph Node Sampling;   Drug: Irinotecan;   Drug: Ifosfamide;   Drug: Etoposide;   Drug: Etoposide Phosphate;   Drug: Doxorubicin;   Drug: Dexrazoxane
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting - verified April 2016

  • Condition:   Plasma Cell Myeloma
    Interventions:   Drug: Cyclophosphamide;   Drug: Dexamethasone;   Drug: Ixazomib Citrate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting - verified June 2016

  • Condition:   Newly Diagnosed Ewing Sarcoma
    Interventions:   Drug: Cyclophosphamide;   Device: Doxorubicin;   Drug: Vincristine;   Device: Ifosfamide;   Drug: Etoposide;   Procedure: Surgery;   Radiation: Radiation Therapy*;   Drug: Temozolomide;   Drug: Irinotecan
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting - verified January 2016

  • Condition:   Relapsed B-Cell Acute Lymphoblastic Leukemia
    Interventions:   Procedure: leukapheresis or collection of PBMCs;   Drug: cyclophosphamide based chemotherapy regimens;   Biological: modified T cells
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Dana-Farber Cancer Institute:Dana- Farber/Children's Hospital
    Recruiting - verified February 2016

  • Conditions:   Stage II Diffuse Large B-Cell Lymphoma;   Stage III Diffuse Large B-Cell Lymphoma;   Stage IV Diffuse Large B-Cell Lymphoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Drug: Prednisone;   Biological: Rituximab;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified March 2016

  • Conditions:   GATA2;   Immunodeficiency;   MDS
    Interventions:   Procedure: Allogeneic HSC;   Drug: Busulfan Test dose;   Drug: Fludarabine(Fludara, Berlex Laboratories);   Drug: Busulfan (Busulfex);   Drug: Cyclophosphamide(CTX, Cytoxan);   Procedure: Total Body Irradiation (TBI);   Drug: Equine Anti-Thymocyte Globulin
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified March 2016

  • Condition:   Hodgkin Disease
    Interventions:   Drug: ABVE-PC;   Drug: DECA
    Sponsors:   Baylor College of Medicine;   Texas Children's Hospital
    Recruiting - verified September 2015

  • Condition:   Neuroblastoma
    Interventions:   Drug: cyclophosphamide;   Drug: topotecan;   Biological: hu14.18K322A;   Procedure: peripheral blood stem cell harvest;   Procedure: surgical resection;   Drug: cisplatin;   Drug: etoposide;   Drug: doxorubicin;   Drug: vincristine;   Drug: busulfan;   Drug: melphalan;   Biological: peripheral blood stem cell transplantation;   Biological: natural killer cell infusion;   Radiation: radiation therapy;   Biological: GM-CSF;   Biological: G-CSF;   Drug: mesna;   Drug: levetiracetam;   Biological: interleukin-2;   Drug: Isotretinoin
    Sponsors:   St. Jude Children's Research Hospital;   Cookies for Kids' Cancer;   CURE Childhood Cancer, Inc.
    Recruiting - verified April 2016

  • Condition:   Her2-Positive Breast Cancer
    Interventions:   Drug: Pertuzumab;   Drug: Trastuzumab;   Drug: Paclitaxel;   Drug: 5-fluorouracil;   Drug: Epirubicin;   Drug: Cyclophosphamide
    Sponsors:   Lajos Pusztai;   Genentech, Inc.
    Recruiting - verified April 2016

  • Conditions:   Sickle Cell Disease;   Hemoglobinopathies
    Interventions:   Drug: Thymoglobulin;   Drug: Fludarabine;   Drug: Cyclophosphamide (CTX);   Drug: Mesna;   Drug: Sirolimus;   Drug: Mycophenolate mofetil (MMF);   Procedure: Bone marrow transplantation;   Radiation: Total body irradiation
    Sponsor:   Vanderbilt-Ingram Cancer Center
    Recruiting - verified May 2016

  • Conditions:   Locally Advanced Malignant Neoplasm;   Breast Cancer
    Interventions:   Drug: Propranolol;   Other: DOT imaging;   Drug: Paclitaxel;   Drug: Nab-paclitaxel;   Drug: Trastuzumab;   Drug: Pertuzumab;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Procedure: Surgery;   Drug: Premedication;   Drug: Anti-nausea therapy;   Drug: Pegfilgrastim
    Sponsor:   Columbia University
    Recruiting - verified February 2016

  • Conditions:   Metastatic Ocular Melanoma;   Metastatic Uveal Melanoma
    Interventions:   Drug: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: Young TIL
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified June 2016

  • Conditions:   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
    Interventions:   Biological: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Biological: Therapeutic Tumor Infiltrating Lymphocytes
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified December 2015

  • Conditions:   Leukemia;   Lymphoma
    Interventions:   Radiation: Total Lymphoid Irradiation;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Thiotepa;   Drug: Melphalan;   Biological: HPC,A Infusion;   Biological: TC-NK Infusion;   Biological: G-CSF;   Drug: Mesna;   Device: CliniMACS;   Drug: Mycophen0late mofetil
    Sponsors:   St. Jude Children's Research Hospital;   Assisi Foundation
    Recruiting - verified June 2016

  • Condition:   Refractory and/or Relapsed Metastatic Solid Tumors
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Radiation: low dose total body irradiation;   Drug: Melphalan;   Drug: Sirolimus
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center
    Recruiting - verified June 2016

  • Condition:   Breast Cancer
    Interventions:   Drug: Trastuzumab;   Drug: Pertuzumab;   Drug: Paclitaxel;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Procedure: Mastectomy;   Radiation: Radiation Therapy
    Sponsor:   Dana-Farber Cancer Institute
    Recruiting - verified May 2016

  • Condition:   Retinoblastoma
    Interventions:   Drug: vincristine;   Drug: topotecan;   Drug: filgrastim;   Drug: PEG-filgrastim;   Drug: carboplatin;   Other: focal therapy;   Drug: etoposide;   Drug: cyclophosphamide;   Drug: MESNA;   Drug: doxorubicin;   Procedure: enucleation;   Radiation: external beam radiation or proton beam radiation
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting - verified April 2016

  • Conditions:   Anaplastic Large-Cell Lymphoma;   Non-Hodgkin Lymphoma;   T-Cell Lymphoma
    Interventions:   Drug: brentuximab vedotin;   Drug: doxorubicin;   Drug: prednisone;   Drug: vincristine;   Drug: cyclophosphamide
    Sponsors:   Seattle Genetics, Inc.;   Millennium Pharmaceuticals, Inc.
    Recruiting - verified May 2016

  • Condition:   Breast Neoplasms
    Interventions:   Drug: Doxorubicin;   Biological: Trastuzumab;   Drug: Cyclophosphamide;   Drug: Paclitaxel;   Drug: Epirubicin;   Drug: Docetaxel;   Drug: Carboplatin;   Drug: Fluorouracil
    Sponsor:   Washington University School of Medicine
    Recruiting - verified April 2016

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Burkitt Lymphoma;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   de Novo Myelodysplastic Syndromes;   Essential Thrombocythemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Juvenile Myelomonocytic Leukemia;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Polycythemia Vera;   Post-transplant Lymphoproliferative Disorder;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Refractory Cytopenia With Multilineage Dysplasia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Drug: Fludarabine phosphate;   Drug: Thiotepa;   Radiation: Total body irradiation;   Biological: Therapeutic allogeneic lymphocytes;   Drug: Cyclophosphamide;   Procedure: Allogeneic hematopoietic stem cell transplantation (HSCT);   Procedure: Peripheral blood stem cell transplantation;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil
    Sponsor:   Thomas Jefferson University
    Recruiting - verified April 2016

  • Conditions:   Diffuse Large B Cell Lymphoma;   Post Transplant Lymphoproliferative Disorder;   Primary Mediastinal (Thymic) Large B-cell Lymphoma
    Interventions:   Drug: DA-EPOCH-R for DLBCL, PTLD, AND PMBCL;   Drug: Methotrexate;   Drug: Etoposide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Prednisone;   Drug: G-CSF
    Sponsors:   Baylor College of Medicine;   National Cancer Institute (NCI);   Texas Children's Hospital
    Recruiting - verified February 2016

  • Conditions:   Leukemia;   Multiple Myeloma;   Myelodysplastic Syndrome;   Non-Hodgkin's Lymphoma
    Interventions:   Biological: Palifermin;   Biological: Lupron;   Procedure: peripheral blood stem cell transplantation;   Radiation: Total-Body Irradiation (TBI);   Drug: Thiotepa;   Drug: Cyclophosphamide
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Swedish Orphan Biovitrum
    Recruiting - verified March 2016

  • Condition:   Melanoma
    Interventions:   Drug: Cytoxan;   Drug: Mesna;   Drug: Fludarabine monophosphate;   Procedure: T cell Infusion;   Drug: IL-2;   Other: Questionnaire
    Sponsors:   M.D. Anderson Cancer Center;   National Institutes of Health (NIH);   National Cancer Institute (NCI);   Prometheus Laboratories;   Key Biologics, LLC
    Recruiting - verified March 2016

  • Conditions:   Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia
    Interventions:   Drug: decitabine;   Drug: fludarabine phosphate;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: tacrolimus;   Drug: mycophenolate mofetil;   Biological: filgrastim;   Radiation: total-body irradiation;   Procedure: allogeneic bone marrow transplantation;   Other: laboratory biomarker analysis
    Sponsors:   University of Wisconsin, Madison;   National Cancer Institute (NCI)
    Recruiting - verified February 2016

  • Conditions:   Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood B-Lymphoblastic Lymphoma
    Interventions:   Drug: dexamethasone;   Drug: vincristine sulfate;   Biological: rituximab;   Drug: clofarabine;   Drug: cyclophosphamide;   Drug: etoposide;   Biological: aldesleukin;   Drug: pegaspargase;   Drug: methotrexate;   Drug: mercaptopurine;   Drug: cytarabine;   Drug: mitoxantrone;   Drug: teniposide;   Drug: vinblastine;   Biological: natural killer cell infusion;   Other: laboratory biomarker analysis;   Drug: therapeutic hydrocortisone;   Procedure: allogeneic hematopoietic stem cell transplantation
    Sponsors:   St. Jude Children's Research Hospital;   Cookies for Kids' Cancer;   Assisi Foundation
    Recruiting - verified May 2016

  • Condition:   Malignant Neoplasm
    Interventions:   Biological: aldesleukin;   Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Other: laboratory biomarker analysis;   Biological: NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL;   Biological: dendritic cell vaccine therapy;   Radiation: fludeoxyglucose F 18;   Procedure: positron emission tomography
    Sponsor:   Jonsson Comprehensive Cancer Center
    Recruiting - verified March 2016

  • Conditions:   Acute Biphenotypic Leukemia;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia in Remission;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Mixed Phenotype Acute Leukemia;   Myelodysplastic Syndrome;   Pancytopenia;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Secondary Acute Myeloid Leukemia
    Interventions:   Drug: Cyclophosphamide;   Drug: Cyclosporine;   Procedure: Double-Unit Umbilical Cord Blood Transplantation;   Procedure: Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified March 2016

  • Conditions:   Breast Adenocarcinoma;   Estrogen Receptor Positive;   HER2/Neu Negative;   Recurrent Breast Carcinoma;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
    Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Procedure: Therapeutic Conventional Surgery;   Drug: Triciribine Phosphate
    Sponsors:   Albert Einstein College of Medicine of Yeshiva University;   National Cancer Institute (NCI)
    Recruiting - verified January 2016

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Myelodysplastic Syndrome
    Interventions:   Drug: Allopurinol;   Drug: Keppra;   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Cyclosporine A;   Drug: Mycophenolate mofetil;   Biological: Allogeneic hematopoietic stem cell transplant;   Biological: Filgrastim;   Biological: antithymocyte globulin
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified January 2016

  • Conditions:   Leukemia;   Myelodysplastic Syndrome;   Lymphoma
    Interventions:   Device: CliniMACS Fractionation system (Arm A);   Device: CliniMACS Fractionation system (Arm B)
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting - verified January 2016

  • Condition:   Breast Cancer
    Interventions:   Drug: Cisplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin
    Sponsor:   Beth Israel Deaconess Medical Center
    Recruiting - verified January 2016

  • Condition:   Relapsed or Refractory Systemic Light Chain Amyloidosis
    Interventions:   Drug: IXAZOMIB;   Drug: Dexamethasone;   Drug: Melphalan;   Drug: Cyclophosphamide;   Drug: Thalidomide;   Drug: Lenalidomide
    Sponsor:   Millennium Pharmaceuticals, Inc.
    Recruiting - verified May 2016

  • Condition:   Metastatic Melanoma
    Interventions:   Drug: High Dose Interleukin-2 (IL-2);   Procedure: ACT with TIL Infusion;   Drug: Vemurafenib;   Drug: Lymphodepletion
    Sponsor:   H. Lee Moffitt Cancer Center and Research Institute
    Recruiting - verified May 2016

  • Conditions:   SCID;   Omenn's Syndrome;   Reticular Dysgenesis;   Wiskott-Aldrich Syndrome;   Bare Lymphocyte Syndrome;   Common Variable Immunodeficiency;   Chronic Granulomatous Disease;   CD40 Ligand Deficiency;   Hyper IgM Syndrome;   X-linked Lymphoproliferative Disease;   Hemophagocytic Lymphohistiocytosis;   Griscelli Syndrome;   Chediak-Higashi Syndrome;   Langerhan's Cell Histiocytosis
    Interventions:   Drug: Alemtuzumab 0.3 mg;   Drug: Cyclophosphamide;   Drug: Busulfan;   Biological: Stem Cell Transplantation;   Drug: Fludarabine phosphate 40 mg;   Drug: Melphalan;   Drug: Alemtuzumab 0.2 mg;   Drug: Busulfan;   Drug: Fludarabine phosphate 30 mg;   Drug: MESNA
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified January 2016

  • Condition:   Lupus Nephritis
    Interventions:   Biological: Placebo plus standard therapy;   Biological: Belimumab 10 mg/kg plus standard therapy;   Drug: Standard therapy
    Sponsors:   Human Genome Sciences Inc., a GSK Company;   GlaxoSmithKline
    Recruiting - verified April 2016

  • Condition:   Systemic Lupus Erythematosus
    Interventions:   Biological: Placebo plus standard therapy;   Biological: Belimumab 10 mg/kg plus standard therapy;   Drug: Standard therapy
    Sponsors:   Human Genome Sciences Inc., a GSK Company;   GlaxoSmithKline
    Recruiting - verified June 2016

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myelocytic Leukemia;   Chronic Myelocytic Leukemia;   Juvenile Myelomonocytic Leukemia;   Myelodysplastic Syndrome;   Hodgkin or Non-Hodgkin Lymphoma;   Sarcoma, Myeloid
    Interventions:   Drug: clofarabine;   Drug: cytarabine;   Drug: busulfan;   Drug: Plerixafor;   Drug: cyclophosphamide;   Drug: antithymocyte globulin (rabbit);   Biological: stem cells;   Drug: Tacrolimus;   Drug: mycophenolate mofetil
    Sponsors:   St. Jude Children's Research Hospital;   Assisi Foundation
    Recruiting - verified March 2016

  • Conditions:   Lymphoblastic Leukemia, Acute, Childhood;   Lymphoblastic Lymphoma;   Peripheral T-cell Lymphoma
    Interventions:   Drug: Temsirolimus;   Drug: Etoposide;   Drug: Etoposide;   Drug: Cyclophosphamide;   Drug: Methotrexate;   Drug: Hydrocortisone;   Drug: Cytarabine
    Sponsors:   Therapeutic Advances in Childhood Leukemia Consortium;   Pfizer
    Recruiting - verified May 2016

  • Conditions:   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Neuroblastoma;   Unspecified Childhood Solid Tumor, Protocol Specific
    Interventions:   Drug: crizotinib;   Drug: cyclophosphamide;   Drug: topotecan hydrochloride;   Drug: vincristine sulfate;   Drug: dexrazoxane hydrochloride;   Drug: doxorubicin hydrochloride;   Other: pharmacological study;   Other: laboratory biomarker analysis;   Other: pharmacogenomic studies;   Other: questionnaire administration
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified March 2016

  • Conditions:   Acute Lymphocytic Leukemia;   Acute Myelogenous Leukemia;   Burkitt's Lymphoma;   Follicular Lymphoma;   Hodgkin Lymphoma;   Mantle Cell Lymphoma;   Non-Hodgkin Lymphoma
    Interventions:   Biological: Haploidentical Bone Marrow Transplant;   Biological: Double Umbilical Cord Blood Transplant
    Sponsors:   Medical College of Wisconsin;   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI);   Blood and Marrow Transplant Clinical Trials Network
    Recruiting - verified February 2016

  • Conditions:   Malignant Solid Tumour;   Breast Cancer Nos Metastatic Recurrent;   Neuropathy
    Intervention:   Drug: Eribulin in Combination w/ Cyclophosphamide
    Sponsors:   University of California, San Francisco;   Eisai Inc.
    Recruiting - verified May 2016

  • Conditions:   Breast Cancer;   Obesity
    Interventions:   Drug: Doxorubicin;   Drug: Cyclophosphamide
    Sponsors:   Texas Tech University Health Sciences Center;   University of Texas
    Recruiting - verified April 2016

  • Conditions:   Stage I Mantle Cell Lymphoma;   Stage II Contiguous Mantle Cell Lymphoma;   Stage II Non-Contiguous Mantle Cell Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage IV Mantle Cell Lymphoma
    Interventions:   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Methotrexate;   Biological: Ofatumumab;   Drug: Vincristine Sulfate
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI);   National Comprehensive Cancer Network
    Recruiting - verified April 2016

  • Condition:   Sickle Cell Disease
    Intervention:   Drug: CD34 selected T-cell depleted allogeneic SCT
    Sponsors:   New York Medical College;   Children's Hospital & Research Center Oakland;   Medical College of Wisconsin;   Washington University School of Medicine;   Tufts Medical Center;   University of California, San Francisco;   University of California, Los Angeles;   Miltenyi Biotec GmbH;   Children's Hospital Medical Center, Cincinnati;   Ann and Robert H. Lurie Children's Hospital of Chicago
    Recruiting - verified March 2016

  • Condition:   Pleuropulmonary Blastoma
    Interventions:   Drug: Vincristine;   Drug: Dactinomycin;   Drug: Cyclophosphamide;   Drug: Ifosfamide;   Drug: Doxorubicin
    Sponsor:   Children's Hospitals and Clinics of Minnesota
    Recruiting - verified February 2016

  • Condition:   Scleroderma
    Interventions:   Procedure: Cytoxan rATG/Fludarabine/HSCT;   Procedure: Cytoxan rATG/HSCT
    Sponsor:   Northwestern University
    Recruiting - verified March 2016

  • Condition:   Leukemia
    Interventions:   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Dexamethasone;   Drug: Ponatinib;   Drug: G-CSF (Filgrastim);   Drug: Rituximab;   Drug: Methotrexate;   Drug: Cytarabine;   Drug: Solu-medrol ( Methyl Prednisolone);   Drug: Citrovorum (Leucovorin);   Drug: Prednisone;   Drug: Pegfilgrastim (Neulasta)
    Sponsors:   M.D. Anderson Cancer Center;   Ariad Pharmaceuticals
    Recruiting - verified May 2016

  • Condition:   Lymphoblastic Lymphoma
    Interventions:   Drug: Prednisone;   Drug: Vincristine;   Drug: Daunorubicin;   Drug: PEG-asparaginase;   Drug: Erwinia asparaginase;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Thioguanine;   Drug: Clofarabine;   Drug: Methotrexate;   Drug: Mercaptopurine;   Drug: Dexamethasone;   Drug: Hydrocortisone;   Drug: Etoposide
    Sponsors:   St. Jude Children's Research Hospital;   National University, Singapore
    Recruiting - verified March 2016

  • Conditions:   Breast Cancer;   Metastatic Breast Cancer;   Recurrent Breast Cancer
    Interventions:   Radiation: Radiation;   Drug: Imiquimod;   Drug: Cyclophosphamide
    Sponsors:   New York University School of Medicine;   National Cancer Institute (NCI)
    Recruiting - verified April 2016

  • Condition:   Systemic Scleroderma
    Interventions:   Biological: Anti-Thymocyte Globulin;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Biological: Filgrastim;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Plerixafor;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified January 2016

  • Conditions:   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
    Interventions:   Drug: Cyclophosphamide;   Drug: Dexamethasone;   Drug: Ixazomib Citrate;   Other: Laboratory Biomarker Analysis
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting - verified March 2016

  • Conditions:   B Acute Lymphoblastic Leukemia;   Bone Necrosis;   Central Nervous System Leukemia;   Cognitive Side Effects of Cancer Therapy;   Neurotoxicity Syndrome;   Pain;   Testicular Leukemia;   Therapy-Related Toxicity;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
    Interventions:   Drug: Clofarabine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Hydrocortisone Sodium Succinate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Prednisone;   Radiation: Radiation Therapy;   Drug: Thioguanine;   Drug: Vincristine Sulfate
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified February 2016

  • Conditions:   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Aplastic Anemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Myelodysplastic Syndromes;   Chronic Eosinophilic Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Neutrophilic Leukemia;   Essential Thrombocythemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Juvenile Myelomonocytic Leukemia;   Mastocytosis;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Polycythemia Vera;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Anemia;   Refractory Anemia With Ringed Sideroblasts;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Secondary Myelodysplastic Syndromes;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Waldenström Macroglobulinemia
    Interventions:   Drug: Fludarabine;   Drug: Busulfan;   Radiation: Total Body Irradiation (TBI);   Biological: Donor Lymphocyte Infusion (DLI);   Drug: Cyclophosphamide (CY);   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Device: Allogeneic hematopoietic stem cell transplantation;   Procedure: Peripheral blood stem cell transplantation (PBSCT)
    Sponsor:   Thomas Jefferson University
    Recruiting - verified February 2016

  • Conditions:   Leukemia;   Acute Lymphoblastic Leukemia
    Interventions:   Drug: Inotuzumab Ozogamycin;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Vincristine;   Drug: Dexamethasone;   Drug: Pegfilgrastim;   Drug: Methotrexate;   Drug: Ara-C
    Sponsors:   M.D. Anderson Cancer Center;   Pfizer
    Recruiting - verified December 2015

  • Condition:   Chemotherapy-induced Nausea and Vomiting
    Intervention:   Drug: Palonosetron, ondansetron, dexamethasone
    Sponsors:   Northside Hospital, Inc.;   Blood and Marrow Transplant Group of Georgia
    Recruiting - verified February 2016

  • Condition:   Leukemia
    Interventions:   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Dexamethasone;   Drug: Ofatumumab;   Drug: Methotrexate;   Drug: Cytarabine
    Sponsors:   M.D. Anderson Cancer Center;   Novartis Pharmaceuticals
    Recruiting - verified March 2016

  • Conditions:   Mesothelioma;   Adenocarcinoma of Lung;   Pancreatic Neoplasms
    Interventions:   Drug: Pentostatin;   Drug: Cyclophosphamide;   Biological: SS1(dsFv)PE38 - lot 073I0809;   Biological: SS1(dsFv)PE38 - lot FIL129J01
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified March 2016

  • Condition:   Lymphoma
    Interventions:   Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: prednisone;   Drug: vincristine sulfate;   Other: R-CHOP regimen;   Other: laboratory biomarker analysis;   Radiation: fludeoxyglucose F 18;   Radiation: selective external radiation therapy;   Radiation: yttrium Y 90 ibritumomab tiuxetan
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2015

  • Conditions:   HER2/Neu Negative;   Recurrent Breast Carcinoma;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
    Interventions:   Drug: Cyclophosphamide;   Other: Laboratory Biomarker Analysis;   Drug: Veliparib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified June 2016

  • Condition:   Hematological Malignancies
    Interventions:   Radiation: Total Body Irradiation;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: Fludarabine;   Drug: Busulfan;   Genetic: Hematopoietic stem cell transplantation
    Sponsor:   Thomas Jefferson University
    Recruiting - verified December 2015

  • Conditions:   Myelodysplastic Syndrome RAEB 2;   Acute Lymphocytic Leukemia;   Acute Myelogenous Leukemia;   Myelodysplastic Syndrome RAEB 1
    Interventions:   Procedure: Allogeneic HSC Transplantation;   Drug: Lupron;   Drug: 18F FLT;   Drug: Cyclophosphamide;   Drug: Methotrexate;   Drug: Tacrolimus;   Radiation: Total Body Irradiation
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2016

  • Conditions:   Hodgkin's Lymphoma;   Leukemia;   Myelodysplastic Syndrome(MDS);   Multiple Myeloma;   Non Hodgkin's Lymphoma
    Intervention:   Procedure: Bone Marrow Transplant
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center
    Recruiting - verified May 2016

  • Condition:   Synovial Sarcoma
    Intervention:   Biological: NY-ESO-1(c259)T Cells
    Sponsor:   Adaptimmune
    Recruiting - verified May 2016

  • Condition:   Leukemia
    Interventions:   Drug: Rituximab;   Drug: Imatinib;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Mesna;   Drug: VSLI;   Drug: Solu-Medrol;   Drug: Methotrexate;   Drug: Ara-C;   Drug: G-CSF;   Drug: Pegfilgrastim;   Drug: Dexamethasone
    Sponsors:   M.D. Anderson Cancer Center;   Spectrum Pharmaceuticals, Inc
    Recruiting - verified June 2016

  • Conditions:   Hematologic Malignancies;   Disorder Related to Transplantation;   Hematopoietic Malignancy
    Intervention:   Genetic: Preparative Regimen
    Sponsors:   St. Jude Children's Research Hospital;   The Hartwell Foundation;   Assisi Foundation
    Recruiting - verified April 2016

  • Conditions:   Hematological Malignancies;   Leukemia;   Lymphoma;   Multiple Myeloma;   Hodgkin's Disease
    Intervention:   Device: Matched Sibling Allogeneic Transplantation
    Sponsor:   Thomas Jefferson University
    Recruiting - verified May 2016

  • Conditions:   Squamous Cell Carcinoma of the Oral Cavity;   Squamous Cell Carcinoma of the Soft Palate
    Interventions:   Biological: LI plus CIZ;   Other: Standard of Care (SOC);   Biological: LI + SOC
    Sponsors:   CEL-SCI Corporation;   Teva Pharmaceutical Industries;   Orient Europharma Co., Ltd.
    Recruiting - verified February 2016

  • Condition:   Leukemia
    Interventions:   Drug: Cyclophosphamide;   Drug: Rituximab;   Drug: Sapacitabine
    Sponsors:   M.D. Anderson Cancer Center;   Cyclacel Pharmaceuticals, Inc.;   National Cancer Institute (NCI)
    Recruiting - verified December 2015

  • Condition:   Myeloid Hematological Malignancies
    Interventions:   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Procedure: Cord Blood Stem Cell Infusion
    Sponsors:   Baylor College of Medicine;   Texas Children's Hospital;   Center for Cell and Gene Therapy, Baylor College of Medicine
    Recruiting - verified December 2015

  • Condition:   Multiple Myeloma
    Interventions:   Procedure: Adoptive Immunotherapy;   Biological: Rapamycin-Generated Autologous Th1/Tc1 Cells
    Sponsors:   National Cancer Institute (NCI);   Hackensack University Medical Center;   Georgetown University
    Recruiting - verified March 2016

  • Conditions:   AIDS-Related Diffuse Large Cell Lymphoma;   AIDS-Related Plasmablastic Lymphoma;   AIDS-Related Primary Effusion Lymphoma;   Grade 3b Follicular Lymphoma;   HIV Infection;   Plasmablastic Lymphoma;   Primary Effusion Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage II Contiguous Adult Diffuse Large Cell Lymphoma;   Stage II Grade 3 Contiguous Follicular Lymphoma;   Stage II Grade 3 Non-Contiguous Follicular Lymphoma;   Stage II Non-Contiguous Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Grade 3 Follicular Lymphoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Prednisone;   Biological: Rituximab;   Drug: Vincristine Sulfate;   Drug: Vorinostat
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified March 2016

  • Condition:   Hematologic Malignancies
    Interventions:   Other: Fludarabine, Cytoxan, TBI, Sirolimus + MMF;   Other: Fludarabine, Cytoxan, TBI, Tacrolimus + MMF
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center
    Recruiting - verified May 2016

  • Conditions:   Adult B Lymphoblastic Lymphoma;   Childhood B Acute Lymphoblastic Leukemia;   Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1;   Childhood B Lymphoblastic Lymphoma;   Down Syndrome;   Stage I B Lymphoblastic Lymphoma;   Stage II B Lymphoblastic Lymphoma;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
    Interventions:   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Thioguanine;   Drug: Vincristine Sulfate
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified March 2016

  • Condition:   DOCK8 Deficiency
    Interventions:   Procedure: Reduced-intensity hematopoietic stem cell;   Drug: Fludarabine(Fludara, Berlex Laboratories);   Drug: Cyclophosphamide(CTX, Cytoxan);   Procedure: Total Body Irradiation (TBI);   Drug: Busulfan (Busulfex)
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified June 2016

  • Conditions:   Metastatic Colorectal Cancer;   Metastatic Gastric Cancer;   Metastatic Pancreatic Cancer;   Metastatic Hepatocellular Carcinoma;   Metastatic Cholangiocarcinoma
    Interventions:   Biological: Young TIL;   Drug: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Pembrolizumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified June 2016

  • Condition:   Prostate Cancer
    Interventions:   Biological: engineered autologous T cells;   Drug: cyclophosphamide
    Sponsors:   Memorial Sloan Kettering Cancer Center;   United States Department of Defense
    Recruiting - verified May 2016

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myelogenous Leukemia;   Myelodysplastic Syndrome;   Multiple Myeloma
    Interventions:   Radiation: total body irradiation;   Drug: Thiotepa;   Drug: Cyclophosphamide;   Drug: Busulfan;   Drug: Melphalan;   Drug: Fludarabine;   Drug: Clofarabine;   Procedure: (CliniMACS) T-cell depleted PBSC Transplant
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting - verified March 2016

  • Condition:   Lymphoma
    Interventions:   Drug: ABVD;   Drug: BEACOPP;   Radiation: radiation therapy
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting - verified May 2016

  • Conditions:   Childhood Infratentorial Ependymoma;   Childhood Supratentorial Ependymoma;   Newly Diagnosed Childhood Ependymoma
    Interventions:   Drug: liposomal vincristine sulfate;   Other: clinical observation;   Radiation: 3-dimensional conformal radiation therapy;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: cisplatin;   Other: laboratory biomarker analysis
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified February 2016

  • Condition:   Stages II-III Breast Cancer
    Interventions:   Drug: Nanoparticle Albumin Bound Paclitaxel;   Drug: doxorubicin;   Drug: cyclophosphamide
    Sponsors:   University of Utah;   Celgene Corporation
    Recruiting - verified March 2016

  • Condition:   Pancreatic Cancer
    Intervention:   Biological: PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1 neo vaccine.
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center
    Recruiting - verified March 2016

  • Condition:   Mature B-Cell Lymphoma
    Interventions:   Drug: COPAD;   Drug: COP, COPD M3, CYM;   Drug: COP, COPADM8, CYVE
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting - verified February 2016

  • Conditions:   Breast Neoplasms;   Breast Cancer;   Breast Tumors
    Interventions:   Drug: Standard Therapy;   Drug: AMG 386;   Drug: AMG 479 (Ganitumab) plus Metformin;   Drug: MK-2206 with or without Trastuzumab;   Drug: AMG 386 and Trastuzumab;   Drug: T-DM1 and Pertuzumab;   Drug: Pertuzumab and Trastuzumab;   Drug: Ganetespib;   Drug: ABT-888;   Drug: Neratinib;   Drug: PLX3397;   Drug: Pembrolizumab
    Sponsor:   QuantumLeap Healthcare Collaborative
    Recruiting - verified December 2015

  • Conditions:   Leukemia;   Acute Lymphoblastic Leukemia
    Intervention:   Biological: gene-modified T cells targeted
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting - verified February 2016

  • Condition:   Epidermolysis Bullosa
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Anti-thymocyte globulin;   Drug: Cyclosporine A;   Drug: Mycophenolate mofetil;   Procedure: Mesenchymal stem cell transplantation;   Radiation: Total body irradiation;   Procedure: Bone marrow or umbilical cord blood (UCG) stem cell transplantation
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified May 2016

  • Conditions:   Acute Erythroid Leukemia in Remission;   Acute Leukemia in Remission;   Acute Megakaryoblastic Leukemia;   Acute Myeloid Leukemia in Remission;   Acute Myeloid Leukemia With Inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1;   Acute Myeloid Leukemia With t(6;9)(p23;q34); DEK-NUP214;   Acute Undifferentiated Leukemia;   Adult Acute Lymphoblastic Leukemia in Complete Remission;   Burkitt Lymphoma;   DS Stage II Plasma Cell Myeloma;   DS Stage III Plasma Cell Myeloma;   Myelodysplastic Syndrome;   Recurrent Anaplastic Large Cell Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Recurrent Hodgkin Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma;   Secondary Acute Myeloid Leukemia;   T Lymphoblastic Lymphoma
    Interventions:   Drug: Cyclophosphamide;   Biological: Filgrastim;   Drug: Fludarabine Phosphate;   Procedure: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified June 2016

  • Conditions:   Thymoma;   Thymic Carcinoma.;   Clinical Masaoka Stage II-IVA
    Intervention:   Drug: Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Eli Lilly and Company;   M.D. Anderson Cancer Center;   City of Hope National Medical Center
    Recruiting - verified April 2016

  • Conditions:   B-Cell Prolymphocytic Leukemia;   Plasma Cell Leukemia;   Progression of Multiple Myeloma or Plasma Cell Leukemia;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Non-Hodgkin Lymphoma;   Recurrent Childhood Hodgkin Lymphoma;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Plasma Cell Myeloma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Non-Hodgkin Lymphoma;   Refractory Plasma Cell Myeloma;   Refractory Small Lymphocytic Lymphoma;   T-Cell Prolymphocytic Leukemia;   Waldenstrom Macroglobulinemia
    Interventions:   Procedure: Allogeneic Bone Marrow Transplantation;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Procedure: Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Etoposide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified June 2016

  • Conditions:   Peripheral Blood Stem Cell Transplantation;   Anemia, Sickle Cell;   Graft-Versus-Host Disease;   Sirolimus (Rapamune );   Alemtuzumab (Campath )
    Interventions:   Procedure: PBMC Transplant;   Drug: Alemtuzumab (Campath );   Drug: Sirolimus (Rapamune );   Drug: Cyclophosphamide (Cytoxan );   Procedure: Low Dose Irradiation
    Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified April 2016

  • Condition:   Congenital Pediatric Disorders
    Interventions:   Drug: Busulfan;   Drug: Cytoxan;   Drug: Fludarabine;   Procedure: Cord Blood Stem Cell Infusion
    Sponsors:   Baylor College of Medicine;   Center for Cell and Gene Therapy, Baylor College of Medicine;   Texas Children's Hospital
    Recruiting - verified September 2015

  • Condition:   Adult T-Cell Leukemia (ATL)
    Interventions:   Drug: LMB-2;   Drug: Fludarabine;   Drug: Cyclophosphamide
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified April 2016

  • Condition:   Acute Leukemia (Category)
    Interventions:   Genetic: HSV-Tk;   Other: T-cell depleted or T-cell replete strategies
    Sponsor:   MolMed S.p.A.
    Recruiting - verified April 2016

  • Condition:   Sarcoma
    Interventions:   Genetic: Autologous HER2-specific T cells;   Drug: Fludarabine;   Drug: Cyclophosphamide
    Sponsors:   Baylor College of Medicine;   Texas Children's Hospital;   The Methodist Hospital System;   Center for Cell and Gene Therapy, Baylor College of Medicine
    Recruiting - verified June 2016

  • Condition:   Breast Cancer
    Interventions:   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: paclitaxel;   Genetic: fluorescence in situ hybridization;   Other: immunohistochemistry staining method
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting - verified July 2015

  • Condition:   Metastatic Melanoma
    Interventions:   Biological: F5 TCR transgenic cells and MART-1 peptide pulsed dendritic cells;   Drug: non-myeloablative conditioning chemotherapy
    Sponsors:   Jonsson Comprehensive Cancer Center;   California Institute of Technology;   University of Southern California;   University of Connecticut;   National Cancer Institute (NCI)
    Recruiting - verified March 2016

  • Condition:   Lymphoma
    Interventions:   Biological: G-CSF;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Doxorubicin;   Drug: Etoposide;   Drug: Ifosfamide;   Drug: Leucovorin;   Drug: Mesna;   Drug: Methotrexate;   Drug: Vincristine
    Sponsor:   University of Miami
    Recruiting - verified February 2016

  • Conditions:   Neuroblastoma;   Bone Marrow, Sympathetic Nervous System
    Intervention:   Drug: cyclophosphamide, vincristine, topotecan ,allogeneic NK cells & 3F8
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting - verified March 2016

  • Condition:   Devic's Disease
    Intervention:   Procedure: Hematopoietic stem cell transplantation
    Sponsor:   Northwestern University
    Recruiting - verified March 2016

  • Conditions:   Leukemia;   Myelodysplastic Syndrome;   Non-Hodgkins Lymphoma;   Chronic Myelogenous Leukemia;   Hodgkins Lymphoma
    Intervention:   Other: fludarabine, cyclophosphamide, thiotepa, radiation therapy, unrelated donor umbilical cord blood graft
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting - verified June 2016

  • Condition:   Multiple Myeloma
    Interventions:   Drug: M-VTD-PACE;   Drug: TT3-LITE Regimen (L-TT3)
    Sponsors:   University of Arkansas;   Millennium Pharmaceuticals, Inc.
    Recruiting - verified March 2016

  • Conditions:   Acute Biphenotypic Leukemia;   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Aggressive Non-Hodgkin Lymphoma;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Indolent Non-Hodgkin Lymphoma;   Malignant Lymphoma, Large Cell Type;   Mixed Phenotype Acute Leukemia;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Follicular Lymphoma;   Recurrent Lymphoplasmacytic Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Plasma Cell Myeloma;   Recurrent Small Lymphocytic Lymphoma;   Recurrent T-Cell Non-Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Refractory Follicular Lymphoma;   Refractory Hodgkin Lymphoma;   Refractory Lymphoplasmacytic Lymphoma;   Refractory Mantle Cell Lymphoma;   Refractory Small Lymphocytic Lymphoma;   T-Cell Non-Hodgkin Lymphoma
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified May 2016

  • Conditions:   Acute Biphenotypic Leukemia;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia in Remission;   Adult Acute Lymphoblastic Leukemia in Complete Remission;   Aggressive Non-Hodgkin Lymphoma;   B Acute Lymphoblastic Leukemia With t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1);   B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1;   Burkitt Lymphoma;   Childhood Acute Lymphoblastic Leukemia in Complete Remission;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Lymphoblastic Lymphoma;   Mantle Cell Lymphoma;   Myelofibrosis;   Pancytopenia;   Plasma Cell Myeloma;   Prolymphocytic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Recurrent Follicular Lymphoma;   Recurrent Lymphoplasmacytic Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Anemia With Excess Blasts
    Interventions:   Drug: Cyclophosphamide;   Drug: Cyclosporine;   Procedure: Double-Unit Umbilical Cord Blood Transplantation;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified April 2016

  • Conditions:   Pompe Disease;   Glycogen Storage Disease Type II (GSD-II);   Glycogenesis 2 Acid Maltase Deficiency
    Interventions:   Biological: Myozyme (alglucosidase alfa);   Biological: Myozyme (alglucosidase alfa)
    Sponsor:   Genzyme, a Sanofi Company
    Recruiting - verified March 2016

  • Conditions:   Acute Lymphoblastic Leukemia;   Myelodysplastic Syndrome;   Multiple Myeloma
    Interventions:   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: Fludarabine;   Drug: mycophenolate mofetil;   Radiation: total marrow irradiation;   Procedure: umbilical cord blood transplantation;   Biological: Granulocyte colony-stimulating factor;   Biological: HLA-matched related donor bone marrow
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified January 2016

  • Condition:   Lymphoma
    Interventions:   Biological: pegfilgrastim;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: lenalidomide;   Drug: prednisone;   Drug: vincristine sulfate;   Genetic: polymorphism analysis;   Other: laboratory biomarker analysis
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting - verified January 2016

  • Conditions:   Leukemia;   Lymphoma;   Bone Marrow Failure;   Immunodeficiencies;   Histiocytosis;   Sickle Cell Disease;   Beta Thalassemia;   Inborn Errors of Metabolism
    Interventions:   Drug: Full Intensity with TBI;   Drug: Full Intensity;   Drug: Reduced Intensity;   Drug: Reduced Intensity (Fanconi)
    Sponsor:   New York Medical College
    Recruiting - verified March 2016

  • Condition:   Fanconi Anemia
    Interventions:   Biological: anti-thymocyte globulin;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Procedure: hematopoietic stem cell transplantation;   Drug: methylprednisolone;   Drug: filgrastim;   Drug: cyclosporine;   Drug: Mycophenolate Mofetil
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified January 2016

  • Condition:   Leukemia
    Interventions:   Biological: sargramostim;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: dexamethasone;   Drug: etoposide;   Procedure: bone marrow transplantation;   Procedure: hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified January 2016

  • Conditions:   Systemic Scleroderma;   Severe Systemic Sclerosis
    Interventions:   Drug: fludarabine phosphate;   Drug: Mycophenolic Acid;   Drug: tacrolimus;   Radiation: total-body irradiation;   Procedure: bone marrow transplantation;   Procedure: reduced intensity allogeneic hematopoietic stem cell transplantation;   Procedure: quality-of-life assessment;   Other: laboratory biomarker analysis;   Other: flow cytometry;   Procedure: biopsy;   Drug: cyclophosphamide
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting - verified March 2016

  • Conditions:   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm
    Interventions:   Drug: busulfan;   Drug: cyclophosphamide;   Biological: Stem cell infusion;   Radiation: Total body irradiation
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified January 2016

  • Conditions:   Neuroblastoma;   Medulloblastoma
    Interventions:   Drug: Nifurtimox;   Drug: Cyclophosphamide;   Drug: Topotecan
    Sponsors:   Giselle Sholler;   Bayer
    Recruiting - verified May 2016

  • Condition:   Brain and Central Nervous System Tumors
    Interventions:   Drug: Induction Chemotherapy;   Drug: Low-Risk Therapy;   Drug: High-Risk Therapy;   Drug: Intermediate-Risk Therapy
    Sponsors:   St. Jude Children's Research Hospital;   University of Florida;   National Cancer Institute (NCI)
    Recruiting - verified May 2016

  • Conditions:   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Chronic Myelomonocytic Leukemia;   Previously Treated Myelodysplastic Syndrome;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Ring Sideroblasts;   Refractory Cytopenia With Multilineage Dysplasia;   Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts
    Interventions:   Procedure: Allogeneic Bone Marrow Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Radiation: Iodine I 131 Monoclonal Antibody BC8;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified January 2016

  • Condition:   Chronic Granulomatous Disease
    Interventions:   Drug: Busulfan;   Biological: Alemtuzumab;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Cyclosporine;   Procedure: Stem Cell Infusion
    Sponsors:   Baylor College of Medicine;   Texas Children's Hospital
    Recruiting - verified September 2015

  • Condition:   Anemia, Aplastic
    Intervention:   Drug: Cyclophosphamide,Campath IH and TBI
    Sponsor:   Mayo Clinic
    Recruiting - verified March 2016

  • Condition:   Acute Lymphoblastic Leukemia
    Interventions:   Drug: Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine;   Drug: Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Etoposide, Dasatinib
    Sponsors:   St. Jude Children's Research Hospital;   National Cancer Institute (NCI);   Enzon Pharmaceuticals, Inc.;   National Institute of General Medical Sciences (NIGMS)
    Recruiting - verified February 2016

  • Conditions:   Leukemia;   Lymphoblastic Lymphoma;   Leukemia, Lymphoblastic, Acute
    Interventions:   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Methotrexate;   Drug: Vincristine;   Drug: Nelarabine
    Sponsors:   M.D. Anderson Cancer Center;   GlaxoSmithKline
    Recruiting - verified March 2016

  • Condition:   Sickle Cell Disease
    Interventions:   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Drug: Sirolimus;   Procedure: Allogeneic bone marrow transplantation;   Radiation: total-body irradiation;   Drug: Levetiracetam
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified May 2016

  • Condition:   Leukemia
    Interventions:   Biological: therapeutic autologous lymphocytes;   Drug: cyclophosphamide
    Sponsors:   Memorial Sloan Kettering Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified February 2016

  • Conditions:   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
    Interventions:   Drug: Cyclophosphamide;   Other: Laboratory Biomarker Analysis;   Biological: Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter;   Other: Pharmacological Study
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting - verified March 2016

  • Conditions:   Immunodeficiency Syndrome;   Non-Cancer Diagnosis;   Severe Aplastic Anemia
    Interventions:   Procedure: Allogeneic Bone Marrow Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Sirolimus;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified April 2016

  • Condition:   Fanconi Anemia
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Procedure: Total Body Irradiation;   Procedure: Bone Marrow Transplantation;   Drug: Mycophenolate Mofetil;   Drug: Sirolimus
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified January 2016

  • Condition:   Lymphoma
    Interventions:   Drug: carmustine;   Drug: cyclophosphamide;   Drug: etoposide;   Procedure: peripheral blood stem cell transplantation;   Radiation: irradiation therapy;   Biological: G-CSF;   Drug: Cytarabine
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified January 2016

  • Conditions:   Lymphoma;   Leukemia;   Myeloproliferative Disorders;   Multiple Myleoma;   Myelodysplastic Syndrome
    Interventions:   Drug: Rituximab;   Drug: Fludarabine;   Drug: Cyclosporine;   Drug: Etoposide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Cyclophosphamide;   Biological: T-Rapa cell DLI;   Procedure: T cell DLI;   Drug: Prednisone;   Procedure: Allogeneic HSCT;   Drug: Filgrastim
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified April 2016

  • Conditions:   Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myelogenous Leukemia;   Myelofibrosis;   MDS;   Refractory Anemia;   Chronic Lymphocytic Leukemia;   Prolymphocytic Leukemia;   Non-Hodgkin's Lymphoma;   Leukemia;   Lymphoma;   Multiple Myeloma;   Myelodysplastic Syndromes
    Interventions:   Biological: filgrastim;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation;   Radiation: total-body irradiation
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified January 2016

  • Conditions:   Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Myelodysplastic Syndromes
    Interventions:   Biological: anti-thymocyte globulin;   Drug: cyclophosphamide;   Drug: Fludarabine;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation;   Radiation: total body irradiation;   Drug: Sirolimus
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified January 2016

  • Conditions:   Kidney Cancer;   Leukemia;   Lymphoma;   Multiple Myeloma;   Plasma Cell Neoplasm;   Myelodysplastic Syndromes
    Interventions:   Biological: anti-thymocyte globulin;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine;   Drug: mycophenolate mofetil;   Procedure: stem cell transplantation;   Radiation: total body irradiation;   Drug: filgrastim
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified January 2016

  • Condition:   Melanoma
    Interventions:   Biological: Dendritic Cell Immunization;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: T-Cells;   Biological: Interleukin-2;   Drug: Mesna;   Biological: Intrathecal T-Cells;   Biological: Intrathecal Interleukin-2
    Sponsors:   M.D. Anderson Cancer Center;   Prometheus Laboratories;   Key Biologics, LLC;   National Cancer Institute (NCI)
    Recruiting - verified February 2016

  • Condition:   Systemic Lupus Erythematosus
    Intervention:   Biological: Hematopoietic stem cell transplantation
    Sponsor:   Northwestern University
    Recruiting - verified March 2016

  • Condition:   MYOPATHY
    Intervention:   Biological: hematopoietic stem cell transplantation
    Sponsor:   Northwestern University
    Recruiting - verified March 2016

  • Condition:   Multiple Sclerosis
    Interventions:   Procedure: Hematopoietic Stem Cell Therapy;   Drug: Standard treatment with a conventional drug
    Sponsors:   Northwestern University;   Uppsala University;   Sheffield Teaching Hospitals NHS Foundation Trust
    Recruiting - verified June 2016

  • Condition:   Fanconi Anemia
    Interventions:   Biological: anti-thymocyte globulin;   Biological: filgrastim;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: methylprednisolone;   Biological: Hematopoietic stem cell transplantation
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified January 2016

  • Conditions:   Acute Lymphoblastic Leukemia;   Non Hodgkins Lymphoma;   Myelodysplastic Syndrome;   Acute Myeloid Leukemia;   Chronic Myelogenous Leukemia;   Hemophagocytic Lymphohistiocytosis (HLH);   Familial Hemophagocytic Lymphohistiocytosis (FLH);   Viral-associated Hemophagocytic Syndrome (VAHS);   X-linked Lymphoproliferative Disease (XLP)
    Interventions:   Drug: Ara-C;   Drug: Cyclophosphamide;   Biological: Campath-1H;   Radiation: Total Body Irradiation;   Procedure: Stem Cell Infusion
    Sponsors:   Baylor College of Medicine;   Center for Cell and Gene Therapy, Baylor College of Medicine;   Texas Children's Hospital;   The Methodist Hospital System
    Recruiting - verified June 2016

  • Condition:   Multiple Myeloma
    Interventions:   Procedure: Stem Cell Transplant;   Drug: Cyclophosphamide + Mesna;   Drug: Melphalan;   Biological: Granulocyte-colony stimulating factor
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified January 2016

  • Conditions:   Leukemia, Myeloid, Chronic;   AML;   Leukemia, Lymphocytic, Acute;   MDS;   Leukemia, Lymphocytic, Chronic;   JMML;   Hodgkin's Disease;   Non-hodgkin's Lymphoma;   Multiple Myeloma
    Interventions:   Procedure: Stem Cell Transplant;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation;   Drug: Busulfan
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified January 2016

  • Condition:   Breast Cancer
    Interventions:   Drug: Taxotere;   Drug: Adriamycin/Cytoxan;   Drug: docetaxol;   Drug: doxorubicin
    Sponsors:   Baylor Breast Care Center;   Baylor College of Medicine
    Recruiting - verified January 2016

  • Condition:   Juvenile Myelomonocytic Leukemia
    Intervention:   Procedure: Stem Cell Transplant
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified January 2016

  • Conditions:   Lymphoproliferative Disorder;   HHV-8;   Malignancy;   HIV
    Interventions:   Drug: Etoposide;   Drug: Interferon-alpha;   Drug: Rituximab;   Drug: Zidovudine;   Drug: Liposomal Doxorubicin;   Drug: Bortezomib;   Drug: Valganciclovir;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Cyclophosphamide;   Drug: Filgrastim (G-CSF);   Drug: Prednisone;   Drug: Sirolimus
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified March 2016

  • Condition:   Glioma
    Interventions:   Drug: Carboplatin;   Drug: Cyclophosphamide;   Drug: Etoposide Phosphate;   Other: Quality-of-Life Assessment;   Drug: Sodium Thiosulfate
    Sponsors:   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified May 2016

  • Conditions:   Hematologic Disease;   Lymphoma;   Multiple Myeloma;   Myelodysplastic Syndrome;   Myeloproliferative Disorder
    Intervention:   Procedure: Stem cell transplantation
    Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified April 2016

  • Conditions:   Lymphomatoid Granulomatosis;   Granulomatosis, Lymphomatoid;   Non-Hodgkins Lymphoma;   Lymphoproliferative Disorder
    Interventions:   Biological: Interferon;   Drug: Rituxan and EPOCH
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified March 2016


PaidClinicalTrials.orgPaidClinicalTrials.org